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Abstract of Thesis

Characterization of a novel, low shear lattice bioreactor
for expansion of human mesenchymal stem cells
By Andrew Barney Burns

Keck Graduate Institute of Applied Life Sciences: 2019

Human mesenchymal stem cells are an ideal candidate for stem cell therapies. They have
been researched since the 1960’s and can differentiate into many desired functional cell
types without undergoing teratogenesis. However, higher yields are needed for a
marketable, successful stem cell therapy. To accomplish this, cells will have to be
cultured to expand them to therapeutically relevant dosages for multiple patients.
Bioreactor production is an ideal method to solve this problem.
The aim of this thesis is to test and validate a novel bioreactor for the cultivation of
human mesenchymal stem cells. In this work, we investigate a novel suspended matrix
for the culture on human mesenchymal stem cells (hMSCs). Initially we investigated
various fiber meshes, both random and structured, for stem cell growth and morphology.
We also investigated hMSC proliferation on rigid polymers commonly used in 3D
printing. We then took the conditions that worked best in 2D culture and tested them in a
small-scale model of the Express bioreactor from Sepragen.
We have assessed cell growth on 3D printed Polylactic Acid (PLA) matrices and
developed a scale down model bioreactor for development and characterization.
Computational Fluid Dynamic (CFD) modeling was used in parallel with the described
iii
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in-vitro experimentation to characterize shear profiles. From the CFD we were also able
to predict a flow rate which resulted in almost zero shear. What we found was that
hMSCs readily form confluent monolayers on the PLA lattice, and retain their surface
marker expression and stemness. When combined with a short hypoxic treatment, the
cells performed better than control flasks, resulting in a four-fold increase from seed with
no impact on biomarker profile and differentiation ability.
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1 INTRODUCTION
1.1 STEM CELL THERAPY
Stem cell are simultaneously novel and well researched. They were first therapeutically
used in the 1960’s before being formally named, but have recently gained more attention
in the field of regenerative medicine.1 This resurgence in stem cell research is based in its
ability to both self-renew and differentiate into functional cell types. Stem cells differ by
their time and source of harvest and are classified by their potency; Potency here refers to
the number of different cell types the stem cell can become. The potency classifications
for stem cells are: totipotent, pluripotent, multipotent, and unipotent. Totipotent cells are
able to differentiate into all cell types in the body, as well as placental tissue. Pluripotent
cells can become all cells of the body. Multipotent cells can become all cell types of a
certain germ layer. Unipotent stem cells are restricted to one cell type and have been
simply referred to as progenitor cells.2 A comparison of stem cell types in regards to
therapeutic potential can be found in Table 2-1.
Pluripotent human Embryonic Stem Cells (hESCs) are collected from the inner cell mass
of the blastocysts. These cells can differentiate into all three germ layers and their
resulting tissues.3 These cells have had a charged ethical history, as a fertilized oocyte
must be sacrificed to harvest these cells. In 2001 the Bush administration placed stringent
regulations on hESC research, resulting in defunded embryonic stem cell research using
primary harvested lines.4 Stem cell research was still conducted, but was limited to
established lines, such as H7 and H9 hESCs. This complicated hESC research, as
laboratories had to split funding and lab space by private investors vs government
1
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funding. It also was detrimental to hESC research, as the available lines were not
genetically diverse.5 Later, the Yamanaka and the Thompson labs both discovered ways
to genetically alter cells and induce a pluripotent state in the cells.6,7 Among the
transcription factors the two labs discovered, the two main genes needed are Oct4 and
Sox2. Additional alternatives include Nanog, FL4, and C-Myc.6,7 Cells treated with these
factors have been deemed induced pluripotent stem cells (iPSCs). This cell type usually
uses a feeder cell culture such as mouse embryonic fibroblast to provide a supportive
culture environment for the cells. Additionally, trypsin cannot be used when passaging
these cells, as hESCs tend to apoptose when placed into single cell suspension. Because
of this, enzymes like accutase are used for cell-substrate detachment to lift cell clusters.
Multipotent stem cells are found in all tissues of the body.8 They are hypothesized to be
surrounded by support cells, forming a favorable niche for the cells to stay quiescent until
called to action via cytokines or stress. These stem cells can give rise to cells only of their
respective germ layer. Though multipotent stem cells have less potency compared to
iPSCs, they are the most studied type of stem cell. This long history stems from their first
use as a treatment for Leukemia.
The first stem cell therapy was performed via bone marrow transplant over 50 years ago
by Dr. E. Donnall Thomas. This treatment replaced the immune system of a leukemia
patient by harvesting bone marrow from a healthy donor and placing it into the ablated
bone of the patient.1 The transplanted bone marrow brought with it both hematopoietic
stem cells and bone marrow derived mesenchymal stem cells. Since the donor and
recipient were twins, there was no issue of host vs graft disease. As research in tissue
transplantation continued, it was discovered that Human Leukocyte Antigen (HLA) was
2
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key in graft vs host disease. Allogenic grafts are now possible by matching donor and
recipient based on HLA. This breakthrough opened the door for stem cell treatments.
Companies like AlloSource, NuVasive, Osiris, OrthoFix, and others have been approved
as combination medical devices and Human Cells and Tissues/Products (HCT/P), and are
currently sold in the United States under the guidance of 21 CFR 361.9 They have been
used for bone regeneration, soft tissue repair, and spinal bone regeneration. They have
been approved through the 501k pathway, meaning the device must show equivalence to
an already approved medical device. For the transplanted cells to remain compliant under
21 CFR 361, the cell product used with these devices must remain minimally
manipulated, otherwise it would have to be approved as a BLA or another more
complicated avenue. One issue specifically with HCT/P is that they do not have to show
equivalence or go through normal clinical trials for approval. This can result in
ineffective therapies and can potentially harm patients.
The current demand for stem cells far exceeds their supply. Recent projections estimate a
31.1% compound annual growth rate of the stem cell market from 2016 to 2022.10 As
demand grows, there have been various attempts to culture these cells in the hope of
increasing the supply for allogenic stem cell therapies and their testing. Cell culture and
cryopreservation are expected to cost over $10 billion by 2020.11 Conventional culture
systems cannot produce these numbers, as culturing stem cells is comparatively harder
than other cells.
Stem cells are very sensitive to chemical and mechanical cues. Such forces can cause the
cells to differentiate, become quiescent, or apoptose.12,13 They are also slow growing,
which pushes out harvest time and increases the risk of contamination. The media also
3
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must contain recombinant factors, which makes it expensive and usually undefined.9
Furthermore, they are adherent dependent, and as such will not readily grow in
conventional bioreactors for culture of CHO or other suspension-adapted cell lines.
Because of this restriction, scale out, rather than scale up, methods of culture are
generally adopted.

1.2 AIM AND SCOPE
High purity, high density culture methods for mesenchymal stem cells are necessary for
stem cell based therapies to be fully realized. Conventional bioproduction techniques
have been used to culture stem cells with cell based therapies in mind, however these
techniques are generally cumbersome and prone to contamination which can result in
impure cell populations. Here we investigate a custom system for high purity, scalable
culture of human mesenchymal stem cells. The main drawbacks of other systems include
lack of cell monitoring, shear stress from mixing techniques, and heterogeneity in the
system due to a combination of these factors. These prompted the design of the core of
the system to facilitate mesenchymal stem cell growth in a homogenous lattice matrix
comprised of biocompatible polymers and materials which would not lead to impurities
in the cell harvest.

1.3 SIGNIFICANCE OF THE RESEARCH
Stem cell culture is inherently more difficult to scale than conventional cell cultures.
hMSCs are very shear sensitive, which leads to low and impure cell harvests. Here we
show a system that performs better than conventional spinner flasks and tissue culture
flasks. The research was performed as a means of high density, pure stem cell culture.
4
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The footprint is less than that of a standard T75 tissue culture flask, but produces double
the yield with better purity.

1.4 OVERVIEW OF THE STUDY
The background focuses on hMSC bioproduction to provide understanding of existing
systems, both in their advances and their shortcomings. The following chapters outline
the testing of various polymer types for cell culture and their basic surface chemistries,
oxygen tension and its effect on stem cell proliferation and stemness, culture in a
dynamic 3D culture system, and computational characterization of the system. The
chapters are written in the form of individual manuscripts that together provide a
complete overview of the tested system in regards to hMSC bioproduction.

2 LITERATURE REVIEW
2.1 MESENCHYMAL STEM CELLS
Adult Mesenchymal Stem Cells (MSCs) are an anchorage dependent stem cell harvested
from adult tissues. Typical sources include the marrow of the iliac crest, the head of the
femur, adipose tissue, peripheral blood, Warton jelly, and umbilical cord blood.14 MSCs
were first described by Dr. Friedenstien, who was able to show the existence of a clonal
subpopulation of cells in the spleen and blood producing organs of mice.15 Their harvest
amounts vary drastically by their source, with up to 500 times higher yields from fat than
from bone.14,16,17 They are described as fusiform, fibroblast-like cells, and often appear
spindle-like under phase contrast.18 They are characterized via surface marker expression,
5
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gene expression of stemness genes, and the cells that they can differentiate into. Research
has shown that hMSCs are positive for the cell surface markers CD166, CD105, CD90
CD73, CD44, CD29, and STRO1 and negative for CD45 CD34, CD19, and CD14.18–21
Some variation in expression of these markers exist, but this may be explained by
variations in the culture methods as well as the age of the cell.18 Due to variation, the
International Society for Cell Therapies (ISCT) has released documentation stating that
the minimal criteria to characterize hMSCs for therapies is: greater than 95% expression
of CD105, CD73, and CD90, and lack CD45, CD34, CD14 or CD11b, CD79α or CD19,
and HLA class II.22 They must also adhere to plastic, and maintain their osteocyte,
adipocyte, and chondrocyte differentiation ability. Though not an ISCT criteria, it has
been shown that they express the stemness genes SOX2 and NANOG.23 They can
differentiate into cells of the mesoderm, including adipocytes, osteocytes, chondrocytes,
myocytes, cardiomyocytes, and tenocytes (Figure 2-1).24 There has also been some
investigation into the still controversial transdifferentiation of hMSCs, resulting in
pancreatic islet cells, corneal epithelium, and nervous tissue.25–27 This type of change
results in the cells entering a dedifferentiated state similar to IPSCs, then differentiating
down another germ lineage.
Differentiation is normally controlled through a mix of cytokines, cell mediated cues, and
external forces. Cytokines and soluble factors can be added to basal media and change
gene expression through cellular pathways.28–30 External forces such as shear and
topologies can also lead to differentiation. Osteocyte differentiation can occur with
exposure to as little as 10 dynes/cm2, and higher rates can lead to apoptosis.31 Culture
methods emphasizing strong binding to ECM or substrates show less stemness, while cell
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culture comprised of mainly cell-cell junctions promoted stemness.23 Nanotopographies
have also been implicated in stem cell differentiation, leading to osteocyte
production.32,33 Substrate stiffness also plays a large role in hMSC fate; softer substrates
tend to produce chondrocytes and adipocytes, while stiffer materials favor osteocyte
differentiation.34–36 The explanation for this is that the culturing substrate matches the
final environment of the cell, which leads it to differentiate into the cell best suited for
that environment.
hMSCs tend to reach senescence after 24 to 40 population doublings, depending on the
age of the donor. The younger the donor, the more doublings were possible before the
hMSCs showed signs of senecensce.18 This is caused by several factors including
damages to DNA, changes in mitochondria, abnormal protein accumulation, and the lack
of telomerase to maintain proper telomere length.37–39
Their ability to differentiate into such a variety of functional cell types, combined with
proven benefit in the treatment of inflammatory diseases, along with their ease of
culturing compared to other types of stem cells has made them crucial candidates in
regenerative medicine.40,41 This is because hMSCs are immunotolerant and
immunomodulatory cells.42,43 It has been shown that this is partially due to a paracrine
signal molecule secreted by hMSCs.44,45 One example of hMSCs’ role in the immune
response was shown when hMSC conditioned media inhibited t-cell activation. This
immunomodulation has become a unique characteristic used in identifying these cells.46,47
Part of this ability may come from secretory vesicles known as exosomes, which are
discussed later in the text. A brief list of diseases where hMSCs are currently being
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investigated includes cardiovascular diseases, diabetes, various immunomodulatory
diseases, and bone disorders.
Myocardial Infarction
More commonly known as heart attack, Myocardial Infraction (MI) is caused by
ischemia to the heart. This results in damage to cardiomyocytes, decreased heart function,
and possibly death. There are approximately 790,000 new MI cases every year in the
United States,48 and costs approximately $108 billion each year.49 Though hMSCs have
the ability to differentiate directly into cardiomyocytes and replace lost function, the
exact mechanism of heart repair is still unclear. Resurgence in cardiac function may also
come from angiogenesis, which results in the growth of new vessels which reestablish
blood flow to infarcted areas of the heart. 50–52 It has also been found that hMSCs have a
cytoprotectant effect on cardiomyocytes.53 In mice, autologous mesenchymal stem cell
transplantation into the heart results in a 40% increase in capillary density, as well as
increased ventricular contractility.51 A human clinical study investigating the heart
function restoration through hMSC implantation found that left ventricular ejection
fraction of the heart increased by 3.84%.54 Incidence of re-hospitalization for heart failure
also dropped in hMSC treated patients.54
Research has also shown that the factors released from hMSCs were able protect
infarcted regions from cell necrosis and prevent scar tissue formation in rats.55 This was
achieved by transplantation of a cell-laden hydrogel onto the infarcted region. Pore sizes
in the gel construct used to anchor cells to the heart were 11nm, small enough to allow
signaling molecules, but would stop larger extracellular vesicles or cells themselves from
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escaping the hydrogel. 2x106 cells per mL were needed to achieve similar levels of
ejection fraction and stroke volume as control groups.
Diabetes
Diabetes is a disease in which the body cannot regulate glucose levels in the blood. This
can cause complications such as neuropathy and damage to microvasculature.56,57
Researchers have shown that hMSCs can be used to treat neuropathy and vascular
damages resulting from diabetes mellitus.57 hMSCs have been found to play an important
role in in tissue repair to lower blood glucose levels.58,59 They are also able to treat
diabetic neuropathy through a paracrine effect.56,57,60 Vascular Endothelial Growth Factor
is one the many cytokines secreted by hMSCs and is the main chemokine of
angiogenesis. When combined with the immunosuppressive properties of hMSCs, this
can restore lost microvasculature.56,57,61 Adult hMSCs also have been implicated in
neuroprotection. Implantation of hMSCs into animal models of Parkinson’s disease
showed a decrease in dopaminergic cell and Perkinje cell loss, showing their
neuroprotective nature.62
Research has also shown how hMSCs repair both beta islet cells and renal glomeruli in
mice models of diabetes. hMSCs lowered blood glucose and increased circulating levels
of insulin.59 The stem cells were introduced through intracardial infusion, but human
pancreatic islets and beta cells were found in the pancreas. Human cells were also found
in the kidneys, making up parts of the glomerulus.

9
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Skeletal Diseases
Osteoarthritis affects 27 million people in the United States and is the most common joint
disorder in the country.63 This disorder causes articular cartilage damage, resulting in
bone on bone movement, inflammation of joints, and pain. It is the leading cause of
disability in the elderly, and it is estimated that 10-15% of adults over 60 years of age
will develop osteoarthritis.64 Current therapies do not repair the damage causing the pain,
and merely treat the symptoms rather than the cause. In a human trial, 108 hMSCs were
injected into the articular cartilage of patients. The patients showed significant
improvement in pain and function with no adverse events.65 Cartilage defects were also
reduced through regeneration of hyaline-like articular cartilage. The hMSC paracrine
effect has also shown importance in treatment of osteoarthritis, decreasing inflammatory
injury and decreasing chondrocyte migration.66,67 Because of this, many researchers are
currently investigating the secretome of hMSCs for treatment of osteoarthritis.66,68,69
Osteoporosis is the progressive loss of bone mass over time. It is generally age related
and affects millions of individuals worldwide.70 Bone loss can be so significant that
patients can become bed ridden from sever fractures. Normally osteoblast cells rebuild
the bone in balance with osteoclasts resorbing old bone. In osteoporosis, the balance is
skewed where breakdown outweighs deposition of new bone. Current therapies mainly
prevent further bone loss. Research has shown that hMSCs are a possible means of
treating this disease and rebuilding lost bone.70 This is because of their ability to
differentiate into osteoblasts and directly increase bone mass.
One shared problem across these various diseases is that they all theoretically require
massive amounts of cells. For MI, it is estimated that up to one billion cells are needed to
10
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substantially reverse damage to the heart.54,71,72 For diabetes and osteoporosis, it is
estimated that hundreds of millions of cells are needed for successful therapies.65 Harvest
alone cannot yield the necessary numbers to treat millions of patients, thus culture is
necessary for commercialized allogenic hMSC therapies to become reality.

2.2 HMSC CULTURE
MSCs are generally regarded as easier to culture than embryonic stem cells and are also
of less ethical concern. Unlike ESCs and IPSCs, they do not undergo teratogenesis, which
eases regulatory concerns. These cells are described to have a fibrotic morphology, and
do not require co-culture with support cells like hESCs have historically needed.73 Unlike
their pluripotent counterparts, they can also be passaged as single cells in which
passaging must be done with accutase or collagenase to leave cell clusters.73,74 This
makes subculturing much easier because it is possible to attain distribution of single cells.
This also has the added effect of increasing homogeneity in cell culture.
Media used for stem cells is generally costly, and hMSCs are no exception. One reason is
because serum and cytokines are needed in the media to maintain stemness. Typically,
the two main cytokines for hMSC culture are recombinant human insulin like growth
factor one (IGF-1) and recombinant human beta fibroblast growth factor (b-FGF). Fetal
Bovine Serum (FBS) is also added to the media. FBS generally ranges from 5% to 10%
v/v of media composition, usually in Dulbecco’s Minimum Essential Media (DMEM) or
alpha MEM.75 It is supplemented with amino acids and can have antibiotics added to
combat microbial contamination. Due to the high cost of media, it is difficult to run such
systems in perfusion, especially in academia. Because serum is used, the media is
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chemically undefined. For regulatory purposes, there is active research into alternatives
for serum. Xeno-free alternatives like human platelet lysate have been used, and though
they are generally recognized as safer than serum, there is still a possibility of
transmitting human diseases and infectious agents. Human platelet lysate is also
expensive, as it must be harvested, stringently tested, and processed before use.
Chemically defined media is commercially available as well, which forgoes all serum and
its harvested likeness. There is much variation of biomarker characterization, cell
proliferation, and subsequent stemness of the cells harvested between all these various
types of media,75,76 all of which are qualities used by the ISCT as means of quality
control.
Traditionally hMSCs are cultured on t-flasks. This static 2D culture can produce
relatively pure stem cells in a reasonable time. In the lab we found a consistent cell yield
of 1.2x106 to 1.4x106 BM-hMSCs from one T75 flask, equating to around 60,000 to
70,000 cells/mL. To scale this method and increase cell yields to meet the quantities
needed for successful therapies, researchers have used roller bottles and Multiplate
stacks. Roller bottles increase surface area by allowing cells to grow on the walls of the
cylinder. The bottles are placed on their sides, filled with just enough media to cover the
bottom side, and gently rolled via a rack system. As the bottle turns the cells are
systematically washed with media. This style of culture has fallen out of favor for the
simpler and larger SA:V ratio of Multiplate flasks. Multiplate stacks like Nunc Cell
Factory (Thermo Fisher) and the Corning Cell Stack (Corning) combine many flat culture
areas into one flask. They contain between 1 to 40 stacks, with newer system containing
up to 120 layers.77 Both roller bottles and Multiplate systems ease operator burden, but
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still have their limitations; it is difficult to monitor and control the cells, and hard to
ensure even distribution of the cells across the culture surface. Improper seeding and lack
of monitoring can lead to poor yields and heterogeneity in harvest. As such, more
controllable bioreactors have been a hot topic of research regarding stem cell culture.
The goal of scale out systems using such bioreactors is to produce high quality stem cells
in large enough quantities for therapeutic needs. It is estimated that between 106 and 109
stem cells per kilogram weight per patient are needed to treat diseases such as diabetes
and myocardial infarction.72,78–81 This large number is due the combination of attrition of
stem cells through migration, unwanted differentiation, and apoptosis. The only way to
reach the large numbers needed for therapeutic dosages is through cell culture.
Furthermore, more than one dose may be necessary to combat this attrition and fully treat
the disease. When required the dosage is multiplied across the thousands of patients
included in a phase III clinical trial, it becomes clear why the vast majority of allogenic
trials currently listed are in Phase I and II. Bioreactors have been investigated for higher
density stem cell culture to address this.

2.3 BIOREACTOR CULTURING METHODS
Conventional bioreactors for suspension-adapted cell culture are inherently unfavorable
for stem cell culture. They are traditionally impeller driven, resulting in higher than
desired shear for the delicate stem cells. They also provide no surface for the cells to
adhere and grow. This means that more customized solutions for old reactor styles, or
completely new reactors must be made to match the requirements of stem cells. When
designing such systems for cell growth, the main points of consideration are: the surface
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area available to the cells, the hydrodynamic forces the cells experience in such a system,
nutrient gradients in the system that may result from non-impeller driven mixing, and
ways of detecting and sampling the cells. With these factors in mind, two main methods
have evolved for stem cell culture; suspension cultures using microcarriers, or
immobilized/fixed bed reactors. From a research landscape study, it was found that the
majority of studies (57%) used bone marrow derived hMSCs (BM-hMSCs).75 It also
found that microcarriers were the favored method of expansion (52.2%). A comparison of
fold increase vs hMSC source also showed that adipose derived hMSCs (AD-hMSCs)
generally achieved higher average expansion factors compared to other sources. One
point worth mentioning is that a group of high performing multiplate static cultures
reported in this paper came from the same lab which was seeding at 30-40cells/cm2
(compared to the recommended 5000cells/cm2).75 Evidence has shown that lower seed
densities increase the rate of population doubling, which increases the expansion factor.82
Low density seeding also has the benefit of maintaining stemness, as researchers found
that cell-cell contact at high confluency decreased CD105 and had a lower percentage of
senescent cells.82 Some other attributes that a reactor should have are: scalability, ease of
use, ease of harvest, automation, and cost effectiveness. A comparison table of culture
methods can be seen in Table 2-2.
Microcarrier Based
The most common route has been to use microcarriers in traditional bioreactors for
suspension cell types. These are polymer spheres ranging from 100 to 300 microns in
diameter, and provide the stem cells a surface on which to grow while in a suspension
system. Using these carriers allow high density cultures because of the large surface area
14
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to volume ratio, with minimal design changes needed on traditional stirred tank
bioreactors. Cells are adherent on free-floating structures, so direct sampling of cells is
easily performed by a media draw. Microcarriers can vary in composition from nondegradable plastics, to dextran, to enzymatically digestible polymers.9 Some macroporous
carriers allow the stem cells to grow inside of the microcarrier itself, protecting it from
strong hydrodynamic forces.83 These carriers can be used in conjunction with various
bioreactor culture systems, the most common being stirred tank reactors and wave bags.
2.3.1.1 Stirred Tank reactors and Spinner Flasks
Traditionally used with CHO and considered the workhorse of bioprocessing, spinner
flasks and stirred tank reactors are commonly used for seed train and cell expansion.
They consist of a centrally located, magnetically or mechanically driven impeller. The
impeller provides even distribution of gas and nutrients to cells. Oxygen transfer can be
performed using a submerged sparger below the impeller, or simply though the gas-liquid
interface at less than 1 liter.77 Using such a system provides more control over cell culture
conditions than static flasks, as agitation provides a more homogenous environment and
inline process parameters can be used to monitor metabolites, pH, temperature, and
Dissolved Oxygen (DO).9,77,84,85 These systems can then be run in fed batch or perfusion
to adjust parameters accordingly and maintain an optimal environment for cell growth.
Cell expansion varies by harvest source of the mesenchymal stem cells, but falls roughly
between 0.2x106 and 2x106 cells/mL.46,84,86 By using large scale single use STBR
researchers were able to achieve 43 and 58 fold increase in adipose derived hMSCs.24,46
However, the impeller used in this system imparts high shear. hMSCs are very shear
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sensitive, and higher than normal values of shear can lead to cell death and
differentiation.
2.3.1.2 Wave bags
This system utilizes a flexible bag placed on a rocking table. Bags are loaded with media
to the desired volume, and gas is overlaid into the head space to inflate the bag the rest of
the way. Gas exchange and media mixing is controlled by rocking the table. Speed and
angle are what control the rates of mixing. The resulting back and forth movement results
in a wave that moves through the media, mixing the media and suspending MSC laden
microcarriers. This system can also have the same inline process monitoring capacity as
stirred tank systems. Researchers using this system have reported between 0.9x106 and
1.9x106 cells/mL and an overall 5 to 15 fold increase in adipose and placental derived
hMSCs after culture.87,88 There is some concern that the energy required to keep
microcarriers in suspension may be high enough to induce a breaking wave, thus
resulting in very high shear.
2.3.1.3 Paddle Driven/Vertical-Wheel bioreactors
These singe use systems are driven by a centrally located paddle wheel. The bottom of
the reactor is U-shaped with tight clearance (the wheel is approximately 85% the
diameter of the singe use bag insert) between the vertical wheel and the bottom. This
provides a strong sweeping force to suspend the cells with low power input.89 The wheel
is mounted horizontally to the systems, such that the direction of motion drives fluid up,
while two axial paddles provide sideways liquid handling, generating a folding action.90
The paddles of the wheel are large enough that very slow rotation provides sufficient
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lifting force to mix the microcarriers while inferring relatively low shear, creating a
favorable culture environment for microcarrier bound BM-hMSCs.91
Non-Microcarrier based systems
Unlike suspended microcarriers, there are other commercially available systems where
the culture substrate is stationary. Media is flowed around the substrate or over the cell
culture surface. As a whole, these systems offer the same advantages as the microcarrier
based systems mentioned previously (real-time measuring of process parameters), but
since the culture area is not in free suspension, direct cell sampling and visualization is
much harder. However, these systems have the benefit of incredibly high SA:V ratios and
decreased purification at cell harvest because of the geometry and immobility of the
culture substrate. As with microcarriers, enzymes are typically used to detach the cells
from their substrate and from other cells.
2.3.2.1 Packed bed
Another avenue of stem cell bioproduction includes immobilized/fixed bed reactor-based
systems. The culture material can either be packed or held in place (fixed bed) while
media is perfused through the system, or the material can be floating (fluidized bed) in a
chamber while the media is perfused through it. These systems generally use randomized
fibers to provide a large surface area to volume ratio for stem cell culture. Cells grow
adherently on the surface of fibers while media is perfused through the porous fiber
matrix. Researchers have reported fold expansions of 9.2 to 38.7 in such systems using
bone marrow and umbilical cord hMSCs.24,92 The iCELLis by Pall is a commercially sold
fixed bed system which uses PET as its culture substrate.
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2.3.2.2 Hollow fiber
Normally used in downstream filtration, cells can grow in either the lumen or around the
outside of such fibers, and media can be passed through the fibers. An advantage of this
system is can mimic laminar flow through vessel very well. However, as mixing is not
handled in a turbulent manner, media gradients can form in such fiber-based systems.
And since the fibers are locked in place, direct sampling of cells is much more difficult
than with microcarrier based systems. Papers report successful hMSC expansion in GMP
compliant quantum cell hollow fiber system.93–95 and expansion factors of 6.7 to 31.4
were reached using BM-hMSCs.93,94,96,97
2.3.2.3 Parallel plate
Lastly, a derivative of Multiplate systems is the parallel plate bioreactor. This system is a
stack of plastic plates much like static multistack/multiplate flasks already mentioned.
The difference here is that media is flowed from the center radially outward on multiple
plates stacked in one system. Much like hollow fiber-based reactors, nutrient gradients
can form, and direct sampling of the cells is near impossible in such a system. However,
both fiber based and microcarrier based systems boast more surface area to volume than
these systems. One study reported an expansion factor of 3.9 using periosteum derived
hMSCs.98

2.4 POLYMERS USED IN CULTURE
Polymer composition and stiffness are integral in stem cell culture. Stiffer materials have
been shown to increase osteogenesis in hMSCs.36 Cells cultured on polymers with similar
elastic modulus to cancellous bone have been shown to readily differentiate into
18
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osteocytes and start calcium deposition. Conversely, hMSCs cultured on more elastic
substrates will differentiate into chondrocytes.34 The hydrophilicity also has a direct
impact on cell stemness and proliferation. Hydrophilic surfaces decrease cell binding,
which in turn increases cell stemness.23 The reverse is also true, where the greater the cell
adhesion to the substrate due to hydrophilic surfaces decreases differentiation potential.
Polyethylene Terephthalate (PET) and Polyethylene Terephthalate Glycol (PETG) are
both thermoplastic polymer resins from the polyester family. PET and its blends have
been used as a cell culture substrate. It can be electrospun in nanofibers or 3D printed
into shapes.99 PET fibers are currently used as the cell scaffold in the iCELLis reactor.
Researchers discovered that a PET 3D fiber matrix used in the iCELLis reactor both
sustained hMSC culture for 21 days, and increased both CD105 and CD29 markers.100
Polystyrene (PS) is the plastic of choice for cell culture. Tissue culture flasks are made of
PS and treated with plasma or exposed to radiation to expose hydroxyl groups on the
surface.101 These functional groups promote cell attachment and proliferation. This
process exposes hydroxyl groups, which can be used to both coat the dishes with
proteins, and directly promote cell adhesion.
Polycaprolactone (PCL) is a synthetic polymer that has gained interested in cell culture
due to its biocompatibility and biochemical properties.102 It has been electrospun into
nanofibers for the culture of hMSCs and their differentiation into osteocytes.103
Poly Lactic Acid (PLA) is easily 3D printed and generally recognized as safe by the
FDA. It has a Young’s modulus similar to bone, matching the niche of bone derived
hMSCs. Its hydrolysis product is lactic acid, a compound normally found produced by
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metabolism. Previous research has shown that plasma treatment of nonwoven PLA
scaffolds promotes stem cell adhesion and growth.104,105
Hydrogels are an alternative to rigid polymers and plastics. They have been successfully
used for both stem cell culture as well as a means of directing stem cell fate.106 Some
natural polymers used include alginate, Hyaluronic acid, Chitosan, Collagen, and gelatin.
Artificial hydrogels have also been used for this purpose and result in a Xeno-free culture
surface. These include polyvinyl alcohol, polyethylene glycol, and polyacrylamide.
Special polyacrylamide gels are thermoresponsive, allowing different characteristics by
varying temperature. Poly(N-isopropyl acrylamide) (pNIPAAM) has been used to culture
stem cells and allows for non-enzymatic cell lifting.107–109
These polymers have been blended, electrospun, and coated to modulate
biocompatibility, increase binding and proliferation, and allow for resorption into the
body. The latter is done with the intent of stopping stem cells from migrating away from
the surgical site, thus increasing the effectiveness of the stem cell therapy.
Coatings
Most polymers used for cell culture are blended with proteins or coated with proteins
after manufacturing to promote cell adhesion and growth. The most common coatings are
animal derived, and the choice is largely dictated by the cell that is being cultured.
However, the most ubiquitous is gelatin, a denatured form of collagen.
Usually provided as a powder, porcine gelatin is dissolved into deionized water to make a
0.1% solution. This can then be plated onto cell culture surfaces to deposit denatured
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collagen onto the surface.110 This provides a more favorable surface for cells to adhere to
by providing RGD residues for integrin mediated binding.111
Collagen anchorage is dependent on cell recognition of GxOGER residues.110 Collagen I,
II, and II are rich in this peptide sequence.112 Researchers have found that there is more
cross-linking between collagen fibers in 3D culture, decreasing integrin mediated binding
of cells.110 They deduced that cell adhesion was mainly due to entrapment of cells within
the cross-linked ECM.
Laminin is normally found in the basement membrane separating epithelium from the
underlying tissue.113 In studies conducted with cancer cell lines it was found that laminin
promoted cell motility.114 This may be useful as a cell coating where passaging is
performed by addition of new surface area for the cells to migrate to and culture out,
eliminating the need for enzymatic digestion based passaging.
Cell adhesion to fibronectin is integrin mediated via RGDS recognition sites.115
Fibronectin has been shown to promote osteocyte differentiation in hMSCs.116 It is
normally found circulating in blood plasma and plays a large role in wound healing.117
Vitronectin is a glycoprotein found predominately in the serum and in bone.118 It binds
integrin to promote cell adhesion and migration.119 A recombinant form of fibronectin is
commercially available, easing regulatory concerns.
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2.5 ADDITIONAL PARAMETERS IN STEM CELL PROLIFERATION
AND PURITY
Gas control
Research has shown that another method of controlling hMSC proliferation and stemness
is through control of gasses. Physiological oxygen percent in the bone marrow is between
1% and 5%.120,121 By matching oxygen tension normally found in their niche, researchers
have seen significant increases over conventional culture techniques.122,123 Biomarker
profile does not suffer, and cells can still readily differentiate into normal cell types.124,125
Companies like Xcell Biosciences have integrated hypoxic culturing options into their
Avatar incubators, as well as hyperbaric conditions, and have shown that this
combination increases marker expression and proliferation with stem cells.126 This effect
is through hypoxia inducible factors (HIFs) and their downstream effects.123,127 HIF has
also been shown to increase stem cell survival and proliferation.128 Genetically modified
stromal cells showed increased engraftment in ischemic heart tissue.129

2.6 OTHER CONSIDERATIONS
Downstream processes
One commonly overlooked hurdle in stem cell therapy is the downstream purification of
these cells.75 The level of purification needed is heavily reliant on the quality of cells
produced, as well as the materials used in the culture of these cells. As such, some focus
has been placed on microcarrier composition, resulting in digestible polymers and simple
filtration devices to remove microcarriers.9,130–132 This removes the otherwise required
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filtration step to ensure complete removal of microcarriers from cell harvest. The same
applies to porous medium, where thermoresponsive coatings aim to eliminate enzymatic
cell lifting steps altogether.109,133–135 Biocompatible polymers have also shown some
promise in reactor culture, cutting the concern of leachables considerably, while also
possibly eliminating cell removal altogether.108 Implantation of a cell laden scaffold make
of a biocompatible or biodegradable polymer would also help stop stem cell migration to
other parts of the body, theoretically increasing efficacy of the therapy and would also
eliminate the need for cell removal from the culture substrate.103,104,131,136 Such processes
would drastically decrease downstream requirements, though buffer exchange may still
be necessary.
Cryopreservation
An allogenic process for hMSC production would need to be cryopreserved for large
scale distribution. The cells would be shipped to centers where administration would
occur, as it is not feasible to ship and store non-cryopreserved cells. Researchers have
shown that high viability cell recovery under serum free culture and freezing conditions
is possible.137 It is worth noting that this process still uses conventional centrifugation
steps to both suspend cells in cryopreservation media before freezing, and to remove
cryopreservatives. These techniques do not scale well, and concentration and buffer
exchange steps may be better scaled using Tangential Flow filtration.
This downstream step has been tested for hMSC concentration and media exchange with
good results. Researchers found that though the stem cells are easily damaged by shear in
such a system, it can still be used to clarify BM-hMSCs from microcarriers and
concentrate them for further processing.138,139
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Secretome
Exosomes are extracellular vesicles secreted by hMSCs. They are between 30nm and
150nm in diameter and contain cytokines, various types of RNA, and DNA.140–142
Exosomes originate from early endosomes that are modified by the fusion of other
intraluminal vesicles.143 They are released after fusion with the plasma membrane.
Exosomes have been shown to help heal wounds and decrease inflammation.144
MicroRNAs (miRNAs) are one part of these vesicles, and it is thought that they are a
main contributor of free miRNA in circulation.145,146 miRNAs have been shown to play a
role in disease and have been investigated as therapies for inflammatory diseases, ocular
diseases, bone and cartilage disorders, and even some forms of cancer. 66,69,142,144,145
Because exosome-based therapies do not use the whole cell itself, the road to market
approval may be easier and faster. The exosomes can be characterized and do not pose
the same risks as stem cells such as off target differentiation, rare occurrence of
malignancies, and infection.147,148 A perfusion reactor would be a viable option to
produce exosomes, as TFF would stop any cell contamination into the product while
constant media exchange would help guard against product degradation.
Lab on a chip
Drug discovery and testing are currently the costliest steps in producing drugs.
Therapeutic candidates are screened for reactivity in vitro, and when positive targets are
found they are progressed to animal studies to test safety and efficacy. However, animal
testing and its overhead is very costly, and not always predictive of safety in humans.149
One theoretical method to test drug safety on human tissue in a repeatable manner is to
create a tissue or organ sample on a chip.150,151 The goal is not to create the entire organ
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or structure, but merely a functional subunit of the tissue.150 This technology stems from
the ability of a stem cell to give rise to functional cell types which make up specific
tissues. A stem cell can be cultured out and differentiated, resulting in a functional tissue.
The resulting tissue can be tested for drug interaction more holistically than could
otherwise be done with a specific cell type. A therapeutic agent can be tested for toxicity
and effectiveness in closer relation to what would happen in the body. Moreover, stem
cells from diseased patients can be used for disease modeling.152 This has mainly been
advocated with the use of IPSCs, but may also prove useful in MSCs for testing drug
targets for diseases of tissues derived from the mesoderm.

2.7 CONCLUSION
hMSCs have much potential as a marketable autologous and allogenic stem cell therapy.
Over the past few decades scientists have made large leaps in understanding these
extraordinary cells. One general agreement is that large scale culture is needed for a
successful allogenic therapy to be realized. This is because of the theoretically large cell
numbers needed for a therapeutic dose, due to in part to the sensitive nature of stem cells.
There is no consensus on approach, as each system has its own advantages and
disadvantages. Microcarrier based culture utilizes more characterized systems, making
translation into bioreactors simpler. However, the impeller used in stirred tank systems
can result in high shear. Fixed bed reactors and parallel plate reactors remove the need for
an impeller but make it difficult to sample the system and characterize cell morphology.
One commonality in these systems is the need for polymer selection.
To increase binding and stemness of the cells cultured in such systems material scientists
have investigated polymers and polymer blends. hMSCs respond to mechanical cues,
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allowing scientist to drive purity and differentiation without the need of cytokines.
Polymer science has also been used to create a more physiologically similar environment
to the normal cell niche. Microcarriers and fiber based systems have both benefitted from
this, as seen by the use of biocompatible materials, special topologies, and coatings of the
materials.
Hypoxia has been shown in increase both stemness and cell proliferation in hMSC
cultures. Decreasing oxygen percentage mimics the natural niche in bone, much like the
mentality of altering polymer stiffness. This has worked as an effective and simple means
of increase stem cell yields while maintaining cell purity.
Cells grown in these methods have other uses than being implanted as a therapy. Secreted
proteins and vesicles can be harvested from such systems and used themselves as a
possible therapies. Healthy and diseased cells can be cultured out in a bioprocess and
differentiated into tissues. The resulting lab grown tissue can be used as a test for drug
interaction and efficacy. Both of these processes may have a more defined route to
approval and usage then whole cell therapies.
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Table 2-1: Pros and Cons of stem cell types in regard to bioproduction and therapeutic potential.
Stem Cell Type
Embryonic

Induced
Pluripotent
Adult
(Mesenchymal)
Stem Cell

Advantages
High Differentiation Potential
High Passage Potential
-

High Differentiation Potential
High Passage Potential
Easily Sourced
HLA Typed and Banked
Immunoprivilaged
Easy Culture
Historical Use and Widely
Researched

Disadvantages
Hard to Source (ethical issues)
Immune Response
Teratogenic Phase
Patient Specific
Teratogenic Phase
Still Carry Genetic Defects
Low Passage Potential
Multipotent
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Figure 2-1: Brief diagram of differentiation potential of hMSCs. Using factors and seeding techniques
hMSCs can become many desired functional cell types.
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Figure 2-2: Various bioreactor systems for the culture of hMSCs. On the left are common microcarrier
based systems, and on the left are commonly used scaffold based bioreactors. Adapted from Jossen et al. 9
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Table 2-2: Bioreactor systems advantages and disadvantages for the bioproduction of hMSCs.
Method

Bioreactor type

Advantages

Disadvantages

Source

Adherent/
Suspension

Aggregate-based
stirred tank
bioreactor

Homogeneous culture
environment; easy to scale up.

High shear stress. Little nutrient
diffusion into center of
aggregate causing apoptosis.

153–155

Adherent/
Suspension

Microcarrier-based
bioreactor: Stirred
tank, RCCS

Difficult to harvest cells. Still
some possible shear issues.
Limited growth area on
microcarriers.

78,88,109,156

Adherent/
Suspension

Microencapsulationbased bioreactor
stirred tank, RCCS

Support high density cell
culture; regulate cell growth
and differentiation; serve as
cell delivery systems; easy to
scale up.
Protection from shear stress;
provide 3D
microenvironment.

Need to release the cells from
the hydrogels. Can affect
stemness of cells.

157

Adherent/
Suspension

Microcarrier-based
Wave bioreactor

Suitable for hematopoietic
stem cell culture; gentle
mixing, low shear stress, easy
to scale up.
Low shear stress, better
mimics cellular
microenvironment.

Costly. Possible sampling
issues. Required energy for
suspension causing high shear.

78,158

Difficult to scale up and the
culture environment is
inhomogeneous due to the
nutrient and oxygen gradient.
Difficult to monitor and sample
cells.
Difficult to harvest cells. Hard
to visualize cells.

159

Limited in size; hard to scale
up; may not be able to produce
the quantities of cells needed for
some applications.

162

Adherent

Hollow fiber
membrane
bioreactor

Adherent

Immobilized cells in
3D scaffolds: Fixed
bed, fluidized bed,
fibrous bed

Adherent

Rotary cell culture
system (RCCS)

Provide 3D
microenvironment; allow cell
spatial organization; regulate
proliferation, differentiation
and tissue formation.
Low shear stress; good mass
transfer; controlled
oxygenation.

78,160,161
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A

B

Figure 2-3: Different culture methods for reactor culture. A) Cytodex 1 microcarriers with cells adherent
to surface. B) Randomized cellulosic fiber matrix with cells on it. Cells stained with phalloidin green for
imaging purposes. Scale bars are 100 microns
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Figure 2-4: Flow chart of process for whole cell therapy. Upstream processes involve the culture of the
cells, and downstream is comprised of steps to increase purity of the resulting therapeutic.
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Figure 2-5: Lung on a chip. Developed for testing effects safety and efficacy of drugs on lung cells in vitro
accurately. Developed by Wyss Institute for Biologically inspired Engineering and Harvard
University.163This technology can be used in conjunction with bioproduced human stem cells, providing
effective tissue modeling of both normal and potentially diseases tissues and the effects drugs can have on
them.
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3 POLYMERS AND TREATMENTS
3.1 ABSTRACT
In order to reach clinically relevant numbers of hMSCs for stem cell based therapies,
culture techniques must be used. To achieve this, fiber matrices and 3D printed polymers
have been tested. In this work we test stem cell adhesion and growth to PE, silk, and
cellulosic fibers, as well as PETG, T-PU, and PLA 3D printable polymers for used in a
novel 3D bioreactor. Cellulosic fibers supported cell growth, but cells tended to form
undesirable clusters. Gelatinized PLA showed the best cell adhesion and proliferation,
forming monolayers akin to culture on 2D tissue culture dishes. hMSCs were easily
removed and maintained their biomarker phenotype after seven days of culture.

3.2 BACKGROUND AND INTRODUCTION
Mesenchymal stem cells (MSCs) are promising candidates for therapies in the field of
regenerative medicine. They have the ability to differentiate into mesoderm derived cell
types including osteocytes, chondrocytes, adipocytes, and myocytes.1 They are described
as fibrotic and are anchorage dependent cells.2 Factors such as topology and surface
chemistry have been proven to affect the potency of hMSCs.3 As such, proper culture is
heavily reliant on the choice of substrate the cell is grown on.
Softer polymers and blends have been shown to induce hMSCs to a chondrocyte or
adipocyte fate.4 Harder substrates have shown to promote cell elongation and osteocyte
differentiation.5–7 This is thought to be because cartilage has a relatively pliant ECM,
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whereas cancellous bone is comparatively stiffer. This is due in part to their ability to test
the substrate on which they reside, contracting to determine the stiffness of the ECM.8
The cells are therefore fated to become the cells which reside in that level of rigidity.
Researchers in polymer sciences have found that much of cell-substrate binding is
through integrin mediated adhesion.9,10 The Integrin receptors on the surface of the
hMSC recognize certain residues in the extracellular matrix proteins, leading to cell
adhesion.11 The recognition and binding to basal membrane proteins such as collagen,
laminin, and fibronectin are also through integrin binding. The selectivity of the integrin
receptor comes from two subunits which form a dimer, and can vary widely based on the
subunits combined. For example, B1 and A2 dimers selectively recognize DGEA
residues of various collagens and laminin, while B3 AV has been shown to bind RGD
sequences of vitronectin, fibrogen, Von Willebrand factor, thrombospondin, fibronectin,
osteopontin, and collagen.11
hMSCs also rely on cadherin to maintain stemness.12 N-cadherin is involved in cell
migration and wound healing, and is an important protein in connective tissues.13,14
Cadherin is mainly found in cell junctions, binding cells together in tissues.15 it is through
the combination of cadherin and integrin that cells adhere, grow, and proliferate, making
surface chemistry very important in the culture of sensitive cells such as hMSCs.15
Another method of cell adhesion is through exposed hydroxyl groups.16 This is important
for cell adhesion to plastics, a defining characteristic of MSCs.17 Interestingly, carboxyl
groups inhibit cell adhesion.18 Using hydroxyl groups is a good way of reducing the cell
culture reliance on xeno-sourced products, easing regulatory concerns for cell based
products. Secondary to exposing hydroxyl groups, synthetic polymers like poly-D-lysine
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can be bound to plasma treated surfaces to further enhance cell adhesion.19 This is a
means of treating plastics and polymers, therefore, plasma treatment and subsequent
coating has its usefulness in polymer-based 3D scaffolds.20,21
Scaffolds are used when growing cells in 3D cultures. This can be used to both increase
usable surface area and to culture cells into a desired shape. The two main 3D culture
methods are either hydrogel based or hard material support based. Hydrogels are
polymers which swell with water.22 There are both natural ECM based hydrogels and
fully synthetic hydrogels. Both scaffolds and hydrogels are common methods of culturing
cells in 3D. Culturing cells in 3D has shown to increase cell-cell connections, mimicking
natural environments.23 This increase in cell communication has also been linked to
maintaining the stemness of mesenchymal stem cells.12 One way to orient and increase
surface area in such hydrogels and rigid polymer scaffolds is through 3D printing.
3D printing has proven to be a valuable tool in cell culture, specifically in regenerative
medicine and stem cell culture.24 Scientist have been able to regrow bone in sheep using
FDM 3D printing of Polybutylene Terephthalate for MSC growth and differentiation.25
Other common 3D printing thermoplastics used in cell culture are Poly Lactic Acid
(PLA), Polycaprolactone (PCL), and Polyethylene Terephthalate Glycol (PETG).26–29 3D
printing of hydrogels has also proven useful for hindering hMSC mobility and attrition,
which has been hypothesized to decrease effectiveness of hMSC therapies.30 Another
feature of 3D printing is that the shape of the overall scaffold can be tailored to the
intended therapy.
In this work we investigate the effectiveness of various polymers on hMSC growth.
Because of the significant increase in surface area, as well as rigidity desired in potential
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hMSC scaffolds, we focused on both fibers and hard polymers. Cellulosic, silk,
polyethylene, and various polymers used in 3D printing were tested to see if they would
support hMSC culture. Simple surface treatment of PLA was also tested as a means of
increasing cell adhesion. The intention was to see which polymer best sustained hMSC
culture to use in a scale-down model of the Express bioreactor from Sepragen
Corporation (Hayward, CA).

3.3 MATERIALS AND METHODS
Cell culture
3.3.1.1 BEND3 Culture
Murine BEND3 brain endothelial cells were used for cell culture feasibility studies. They
were cultured as per ATCC recommendations. Cells were seeded at 5,000 cells/cm2 for
culture propagation. Media was a high glucose DMED base containing sodium pyruvate
(GIBCO 11995065), supplemented with 10% FBS (ATCC 30-2021) and 1% penicillinstreptomycin (ATCC 30-2300). Cells were passaged using 0.25% Trypsin and 0.53 mM
EDTA solution (ATCC 30-2101). Cells were fed on day 3 and passaged on day 6 or
when confluency reached 90%. Experiments were conducted between passage 5 and 30.
3.3.1.2 hMSC Culture
hMSCs were cultured according to guidelines provided from ATCC. Briefly, cells were
cultured in hMSC media (ATCC PCS-500-030) supplemented with the bone marrow
derived hMSC bullet kit (ATCC PCS-500-041) at 37°C and 5% CO2. A ¾ media
exchange was performed on day 3, and cells were passaged at 80-90% confluency,
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usually on day 6. Cells were lifted using 3.5mL of 0.25% Trypsin and 0.53 mM EDTA
solution (ATCC 30-2101) for regular passaging of T-75 flasks, and cells were re-plated at
5,000 cells cm-2. Working cell bank was created from pass 4 hMSCs and stored in liquid
nitrogen. Experiments using hMSCs were conducted on cells between passage 5 and 9.
Cellulosic scaffold
Cellulosic samples were provided by Sepragen Corporation (Hayward, CA). This
scaffold material is treated to promote cell adhesion and is currently used in their Express
bioreactor line. For test cultures 1cm2 swatches were cut to fit into 12 well plates.
Seeding experiments varied, but included static adhesion, rocking, and gelatin vs
untreated samples. For static seeding a rough estimate of surface area was taken using
porosity found using FIJI. The appropriate cell number was suspended in the volume
necessary to wet the swatch and set overnight in the incubator. The well was then brought
to appropriate volume. Cells were then cultured out for seven days.
For rocking the cells were place in total well volume and the swatch was place with the
cell laden media. The culture plate was then place on an oscillating rocker (Adams
Nutator Model 1105) overnight in 37°C and 5% CO2 incubator.
Cellulosic scaffolds were gelatinized by placing swatches in filtered and autoclavesterilized 0.1% (W/V) porcine gelatin (Fisher 9000-70-8) solution in MQ water. The
submerged swatches were placed at 37°C for 30 minutes. Swatches were then washed
with PBS and cell inoculum was added to the wells or directly to the scaffold depending
on adhesion and culture study.
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For bioreactor studies a swatch of cellulosic was cut, sterilized and gelatinized according
to previous methods. A 50mL conical tube cap was fitted with four ports. One extended
to the middle of the tube, one to the bottom, and two had no extensions. The two without
any internal attachments were for gas exchange. 106 hMSCs were suspended into 15mL
of media and added to the reactor. Seeding circulation started at 5mL min-1 for one hour,
then was set to 2.5mL/min for one hour, then brought down to 1.5mL min-1. Media
circulation was tested between 1.0-2.0mL min-1 for the remainder of the seven days.
Silk and polyester
100% Silk fabric purchased from fabric store was cleaned with hot water and soap.
Swatches were cut and autoclave sterilized for 15 minutes at 112°C. Four swatches of
silk fibers were rewetted in PBS and placed into well plates. Two control wells, two
ungelatinized swatches, and two gelled swatches were seeded at a density of 5,000 cells
cm-2 based on well area. At day seven cells were fixed and stained for visualization using
fluorescent microscopy.
Polyester was sterilized and prepared in the same way as silk fibroin swatches. After a 15
minute autoclave cycle the fabric shape and texture was altered, but still stable enough
for culture. Cells were plated at 5,000 cells cm-2 and cultured for seven days. After which
cells were stained and imaged by fluorescent microscopy.
PLA and plasma etching
PLA scaffolds were 3D printed using a PrintrBot Simple Metal (Printrbot) and Cura 3.2.1
slicing software. Translucent high temperature PLA (Protoplant) was used. PLA was
printed at 212°C. PLA was autoclaved at 121°C for 15 minutes to both sterilize and heat
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treat the PLA. For plasma treatment, samples were first placed in plasma cleaner (Harrick
Plasma, model PDC-32G) set on high for three minutes. Plasma was created under
vacuum without addition of argon or oxygen. Samples were then wetted with MQ water
and autoclave sterilized for 15 minutes before culture.
PETG and T-PU
Polyethylene Terephthalate Glycol (PETG) (3D Solutech) was printed at 207°C. It was
autoclave sterilized for 15 minutes at 121°C. Like the PLA, it was printed in both flat
sheet and lattice form to test cell growth and adhesion. A comparison of gelatinized and
control PET scaffolds was also performed. Thermoplastic Polyurethane (SainSmart) was
printed at 200°C. The same wash and sterilization steps were followed to prepare
Thermoplastic-Polyurethane (T-PU) as with PETG. These samples were not tested with
plasma etching.
Drop test for measuring contact angle
To measure contact angle, a drop test was performed on untreated and treated cell culture
scaffold samples. A 2µL drop of MQ water was made using a micropipette, and the drop
was slowly brought down to the surface being tested. The drop was allowed to contact the
surface and stabilize for 10 seconds. A photograph was taken and uploaded to FIJI
(ImageJ) for analysis. The analysis package used was drop_snake.31 To do this the
photograph was first converted to 8-bit black and white. Then using the software package
the circumference was drawn, and vertexes of the angles noted. The software is then able
to simulate the drop and calculate the contact angle of the drop. Hydrophobic surfaces are
defined as having a contact angle greater than 90 degrees, and hydrophilic angles are less
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than 90 degrees. Each treatment was measured three times and an average contact angle
was calculated.
SEM imaging
PLA matrices were washed and prepared for electron microscopy. Using conductive
double-sided copper tape samples were stuck to 1/2in slotted stages (TED PELLA
16111). Samples were imaged at 2kV using Hitachi SU-70 scanning electron microscope.
Confocal imaging
Cells were grown on various scaffolds and washed using Ca++ and Mg++ PBS. The cells
were then fixed in place with 4% PFA for 15 minutes and washed again with PBS.
Permeabilization was performed using 1% (W/V) Triton-X 100 in PBS for 30 minutes at
37°C. Cells were then washed and placed in 1% (W/V) Bovine Serum Albumin (BSA)
and 0.1% (W/V) Triton-X 100 in PBS for 1 hour at room temperature. Cells were then
stained with 1 drop per mL Phalloidin green (Invitrogen) and 2.3nM DAPI. To visualize
viable cells on the matrix the same wash steps were followed, but cells were not fixed nor
permeabilized. Calcein-AM (ab141420) was used instead of Phalloidin. 1μL of 1mM of
Calcein solution was added to 1mL of Ca++ and Mg++ PBS and cells were incubated for
10 minutes at 37°C. Since Calcein-AM must be processed to fluoresce, no subsequent
washing was performed.
Flow Cytometry
hMSCs were cultured in experimental conditions and lifted with TrypLE-Express to
preserve cell surface receptors. Cells were first washed with PBS, then placed in TyrpLE
for 15 minutes. After neutralization cells were fixed in 4% paraformaldehyde (PFA) for
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15 minutes, washed twice, and blocked for 1 hour at room temperature. Blocking solution
consisted of 1% (W/V) BSA (LONZA) and 0.1 % (W/V) Triton-X 100 in PBS. Cells
were stained for the positive markers CD105 (Invitrogen MHCD10520) and CD73
(Abcam ab157335) and were negative for CD14 (Abcam ab91146) and CD19 (Abcam
ab25510) at 1μL per 500,000 cells in 500μL following recommendations. Samples were
then run at medium speed (35μl min-1) on a BD Accuri C6 flow cytometer and analyzed
using FlowJo V10 (Ashland, OR). Unstained controls were used to gate cells.
Compensation was done through FlowJo and Fluorescence Minus One (FMO)
techniques. Initial bioreactor studies were done using only CD105 and CD34.

3.4 RESULTS
Cultures
Cellulosic scaffold had very poor cell adhesion when un-gelatinized both with Bend3
(Figure 3-1 A) and with hMSCs (Figure 3-2 A). Without gelatin, cells were very
spherical and pseudopodia can be seen unattached to cellulosic material. When
gelatinized many more Bend3 cells can be seen on the cellulosic fibers (Figure 3-1 B).
Furthermore, cell morphology is more similar to normal polystyrene T-flask culture,
showing cell elongation running along the fiber (Figure 3-2 B).
Silk scaffolds showed some cell retention (Figure 3-3 A) but compared to cellulosic and
PLA it performed very poorly. However, cells imaged on silk fabric showed some
colonies forming by day seven. Because of poor growth and adhesion, it was not possible
to run cells though flow to analyze resulting cells.

56

DocuSign Envelope ID: 9BFE76AE-08BD-4F0D-906A-66E514EAA4DB

Polyethylene cultures visually show increased cell adhesion compared to silk fibers
(Figure 3-3 B). However, when cells were lifted from scaffold and analyzed via two
marker flow cytometry it was found that not only were there very few cells to count, but
that cells did not maintain their CD105 marker expression indicating differentiation
(Figure 3-4).
Contact angles were measured via software according to Figure 3-5. The only sample that
showed statistically significant difference to other conditions tested was untreated PLA
(p<0.05). Plasma treated PLA similar hydrophilicity (p>0.05) to PS dishes (Figure 3-6).
Gelatin also resulted in similar contact angles as PS and plasma treated PLA (p>0.05).
Because plasma treatment eliminates the use of animal derived products, we initially
tested cell culture on plasma treated PLA prints. Cell adhesion and morphology of
densely seeded hMSCs on day one appear very similar to polystyrene culture dishes
(Figure 3-7 A). However, by day two very few cells were seen on the scaffold, and
colonies were very sparse (Figure 3-7 B). Values are not reported, but when lifted cell
number were far lower than expected. Gelatin coated PLA showed the same contact angle
as control PS dishes. Because of this, gelatin treatment was used for all subsequent PLA
cultures. Moreover, flow cytometry data showed that the cells that were lifted from
gelatin coated PLA on day seven retained proper four marker cell surface profile (Figure
3-8).
Cells did not readily adhere to TPU, even when gelatinized. Its opacity also made it
difficult to image. PETG scaffolds deformed in the autoclave and poor cell growth was
seen. Because of this these scaffolds were omitted.
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PLA lattice
Though testing of extrusion rates and speeds of the printer it was determined that between
20 and 30mm s-1 using 0.15mm layer height resulted in the best, most homogenous
geometry (Figure 3-9). There were however some abnormalities in the print. At almost all
tested printer speeds there is still a small extra filament crossing the lumen of the channel
(Figure 3-9 A-D). As this would increase surface area and was rather predictable in
printing it was not worrisome. Layer height and extrusion percent were also tested, and it
was found that 0.15mm and 100% extrusion resulted in the most homogenous and
optically clear PLA structures (Figure 3-10). To see surface nanotopology the lattices
were imaged using SEM, which showed very similar surface modalities to polystyrene
(Figure 3-11). However, after optimization it was found that the printer speed could be
increased to 80mm s-1 at a layer height of 0.2mm. This was accomplished by slicing the
object at 50% infill and printing at zero wall thickness. The resulting print was a grid
pattern infill with very homogenous pores and no hanging extrusions or burrs (Figure
3-12).
Bioreactor Culture
Reactor cultures were step up and run according to Figure 3-13 A. The system is made of
a polycarbonate tube and two stainless steel caps on either end to make a chamber. There
is a small pass-through port capped with silicone on the front of the reactor, and four
Luer lock ports on the top. Two ports handle liquids, while the remaining two are 0.2µm
filter capped for gas exchange. Media is circulated by an external peristaltic pump and
gas is overlaid into the chamber at a flow rate of 0.01VVM. Both cellulosic and gelatin
coated PLA were tested in the system. Figure 3-13 B shows how the cellulosic swatch
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was wrapped around a 15mL conical tube suspended in the center of the reactor. The
growth area (PLA or cellulosic) is suspended to allow media to flow through it, creating a
much smaller boundary layer of media above the cells. The media collects at the bottom
and stays in the chamber to maintain humidity, where a drop tube from one of the top
Luer lock ports can then continue recirculation via external peristaltic pump. Initial flow
rates were 1mL min-1 and optimizing seeding procedure led to the largest increase in cells
gained. Recirculating cell suspension resulted in little to no cell yields on day seven.
Cellulosic based cultures supported cell adhesion (Figure 3-14 A) and growth, resulting
in cell clusters within the fiber matrix (Figure 3-14 B). However, significant particulate
collection at the base of the bioreactor reservoir, increasing particulates in solution and in
turn making flow cytometry to quantify cell purity very difficult.
PLA reactor cultures performed better than cellulosic matrix. However, a different
seeding strategy had to be adopted. To properly seed the lattice cells were suspended in
small volumes and injected above the lattice. The cells in media were allowed one hour to
settle and adhere without the reactor recirculating any media. Cells were easily lifted and
characterized via four marker flow cytometry, which showed that cells maintained their
stem cell phenotype (Figure 3-15). Dot-plot density also showed that much more cells
had been harvested than previous runs. Confocal images using Calcein viability staining
showed hMSCs adherent onto the PLA cross lattice in confluent layers of cells after
seven days in culture (Figure 3-16).
Comparing PLA, PS and Cytodex we saw that cellulosic showed the best doubling time (
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Table 3-1). It was found that the substrates and samples tested hade relatively similar
doubling times after seven days in culture. The substrate that showed the most doublings
was PLA in static culture, and the poorest performing was actually ungelatinized static
PS. Unfortunately, this was not done in triplicate, and as such we could not calculate
statistical difference.

3.5 DISCUSSION
TPU was optically opaque, making any cell visualization impossible. As such it was not
pursued as a cell scaffold. Cell monitoring is necessary in reactor cultures, and since cells
could not be easily seen on the substrate it was not used in bioreactor culture. It would be
interesting to use optically clearer filament and test cells for differentiation. As softer
materials have shown to induce chondrocyte differentiation, it may be a new dynamic
culture method to differentiate hMSCs to chondrocytes in-situ.4,7 This is especially true
as polyurethane has been used in cartilage tissue engineering previously.32
PLA plasma treatment resulted in increased cell attachment, but also apoptosis. After
treatment the polymer most likely retained reactive oxygen species on its surface, which
while charging the surface and increasing wettability and adhesion, it also increased cell
death. However, others have successfully used plasma to increase cell adhesion and have
no effect on cell proliferation compared to untreated samples.20 One difference was that
the samples used in that study were ethylene oxide sterilized for four days post plasma
treatment. What may be necessary for future plasma treatment steps is a PBS soak and
time for surface species to dissipate. If cell death due to reactive species was mitigated
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this would be a very scalable and cost-effective means of making a Xeno-free treatment
for 3D cell culture.
Cellulosic scaffolds showed initial promise. Cellulosic is biocompatible and has already
been tested as a drug delivery vehicle.33–35 3D printed cellulosic scaffolds have been
proven to support cell growth.36 However, in this case the cellulose may have been acting
as a filter, catching cells as they passed through the material rather than promoting
adhesion. Initially this was desirable, as cells would become stuck against the lattice
through fluid movement, increasing final yield. However, untreated cellulosic did not
show elongated cells indicative of cell adhesion, and thus cells did not proliferate. When
cellulose was gelatinized the cells tended to grow in clusters, which has been shown to
induce differentiation.37 It has also been shown that aggregate culture decrease overall
proliferation in MSCs, and as such cellulosic material was not pursued further.38–40
Thus, PLA was chosen for its cell adhesion, biodegradability, rigidity, and ease of
manufacturing into 3D lattices.41,42 Cells cultured for seven days retained their biomarker
profile even on PLA in a dynamic culture environment. The decrease in doublings from
static to dynamic culture is best explained by initial cell seating. Untreated PLA has a
very high contact angle, and in dynamic culture would not catch the cells very well. In
static culture though the cells would settle due to gravity, thus the initial seed would be
far more efficient.
Even with this simplified small-scale reactor there were many problems. An Ishikawa
diagram was used to highlight problem areas and possible causes during bioreactor
culture (Figure 3-17). From this the main issues we saw that fittings were the main source
of leakage and contamination. Once identified, the nylon fittings were exchanged for
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polycarbonate Luer lock and stainless-steel barbed fittings, which stopped contamination
and leaking problems.

3.6 CONCLUSION
Gelatinized PLA worked the best of the materials tested. Plasma treatment of the PLA led
to increased hydrophilicity and better wetting. Initially cell cultures plated on plasma
treated PLA showed better adhesion, however by day three cells were very sparse. This
may be due to residual reactive species on the surface of the PLA. Gelatinized cellulosic
also showed promise in cell culture, as cells were seeded in single cell suspension and
colonies were observed by day seven. However, cell harvest was very sparse and
contained degraded fragments of the matrix. Here we have shown that gelatinized 3D
PLA scaffolds can support hMSC growth in a dynamic environment. Cells lifted also
retained their biomarker profile.
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Figure 3-1: Bend3 Cultures on A) untreated control and B) gelatinized cellulosic material in static culture
conditions. Cells were seeded statically by overlaying cell containing media onto scaffolds and culturing
for 24 hours. Green is actin staining.
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Figure 3-2: hMSCs culture on cellulosic fibers after 24 hours. A) Single cell on ungelatinized control and
B) Gelatin coated cellulosic material in seeded statically. Green is actin and blue are the nuclei. Nuclear
staining was not seen in A because of issues with UV laser on the confocal.
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Figure 3-3: hMSCs grown on other fiber lattices for seven days. A) Gelatin coated silk fibroin and B)
gelatin coated Polyethylene. Green is actin and blue are the nuclei.
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Figure 3-4: Flow cytometry of hMSCs grown for seven days on Polyethylene in static culture. Very few
cells recovered from PE fiber swatch, so very few cells were tested for flow cytometry.
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Figure 3-5: Contact angle measurements of PLA. Vertical lines overlaid onto picture of 2µl droplet created
using drop_snake software. The circumference of the drop is outlined through the software, which then
calculates the angle from normal. A) Untreated PLA from printer. B) Three-minute plasma treated PLA.
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Figure 3-6: Contact angles of plastics and treatments calculated via the drop_snake method in FIJI.
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Figure 3-7: hMSCs statically seeded onto plasma treated PLA 2D sheets. A) hMSCs show adhesion to PLA
surface after 24 hours. B) After 48 hours hMSCs appear more sparse on the surface of the plasma treated
PLA. Green is actin and blue are the nuclei.
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Figure 3-8: Static culture of hMSCs on PLA static controls. Cells were fixed, blocked, and stained for
surface markers CD105 CD73 CD19 and CD14. Rows correspond to two different samples.
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Figure 3-9: Printer speed effect on 3D printed PLA lattice pore geometry. Scale bars are 200 microns and
values above images are the printer speed in mm s-1. Viewed from the side (XZ).
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Figure 3-10: Printer setup. Extrusion percent vs layer height. Viewed from the side (XZ). Scale bars are
200 microns.
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Figure 3-11: SEM images of Polystyrene and PLA lattice. Top row shows ungelatinized controls and
bottom are gelatin treated. A) Low magnification image of the side of ungelatinized PLA lattice. B) High
magnification of ungelatinized PLA. C) Ungelatinized PS control culture dish at high magnification. D)
Low magnification of gelatinized PLA lattice from the top view. E) High magnification image of gelatinized
PLA. F) High magnification of gelatinized polystyrene culture plate control.
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Figure 3-12: Improved printing of lattice. By altering G-code 3D printer more homogenous prints were
achieved with less burning and distortion of filaments. A) shows a ZX plane of the print and B) shows a XY
plane.
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Figure 3-13: Bioreactor design using cellulosic scaffold. A) Cartoon diagram showing reactor, reservoir,
peristaltic pump and air pump. B) Assembled cellulosic scaffold-based reactor. Reactor comprised of two
316 stainless steel capping a polycarbonate chamber sealed with high temperature silicone O-rings sealed.
Four threaded Luer loc connectors allow media circulation and gas exchange.
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Figure 3-14: hMSCs cultured for seven days on gelatin treated cellulosic scaffold in dynamic bioreactor
culture. A) Low magnification picture of seeded lattice. B) High magnification of cell cluster grown from
single cell. Green is actin and blue are the nuclei.
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Figure 3-15: F Flowcytometry of hMSCs from PLA Bioreactor lifted on day 7. Cells were cultured in
normoxic conditions in the PLA lattice for seven days prior to lifting and staining. Cells were fixed, blocked
and stained for CD105 and CD34. Each row is one sample.
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Figure 3-16: Cells on improved PLA Lattice. hMSCs were cultured for seven days on the PLA scaffolds in
the bioreactor, then stained for viability. Green is Calcein viability staining.
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Table 3-1 Doubling statistics of hMSCs on various culture substrates

Condition

Doublings Doubling Time (hr)

µ (1/hr)

Fold Increase

PS Static
PS Static 0.1%
Gelatin

1.37

124

0.006

2.93

1.56

109

0.006

-

Cellulosic Matrix

1.81

93

0.007

3.00

PLA Static

2.08

80

0.009

2.69

PLA Dynamic

1.42

120

0.006

2.72
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Figure 3-17: Ishikawa diagram of sensitive processes and problem areas in stem cell culture.
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4 STEM CELL REACTOR CULTURE
4.1 ABSTRACT
Bone marrow derived human Mesenchymal Stem Cell (hMSC) harvest is invasive,
painful, and expensive, which makes it difficult to supply the enormous amount of pure
hMSCs needed for future allogenic therapies. Because of this, a robust method of scaled
bioreactor culture must be designed to supply the need for high purity, high density
hMSC yields. Here we test a scaled down model of a novel bioreactor consisting of a 3D
printed PLA lattice matrix suspended outside of its culture media. The growth matrix is a
uniform and replicable biocompatible 3D printed polylactic acid lattice matrix, which
enables homogenous cell culture in three dimensions. The system tested resulted in
comparable stem cell yields to other cell culture systems using bone marrow derived
hMSCs, while maintaining high purity (>98% expression of combined positive markers),
high viability (96.54% ±2.82), and differentiation ability into functional cell types.

4.2 INTRODUCTION
Stem cells are a major component of regenerative medicine that show promise of curing
chronic diseases and organ regeneration.1 What defines this cell type and cements its
usefulness in regenerative therapies is that stem cells can both self-renew and
differentiate into functional cell types. Stem cells are generally classified into three main
types: embryonic, induced pluripotent, and adult stem cells. Human Mesenchymal Stem
Cells (hMSCs) are a type of adult multipotent stem cell which can differentiate into many
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useful cell types for regenerative medicine including osteocytes, adipocytes,
chondrocytes, myocytes, and cardiomyocytes.2 hMSCs have been widely researched, and
hMSC derived stem cell therapies are currently under clinical trials for cardiovascular,
neurologic, bone and cartilage, lung, kidney, liver, and autoimmune diseases.3 They also
show immunotolerant and immunomodulatory properties in allogenic transplants.2,4
However, bone marrow derived hMSC harvest is invasive, relatively low yield, and
painful, making allogenic therapies difficult and expensive.5
The challenges of creating therapeutic dosages lies in both the number of cells needed for
a successful therapy, and the sensitive nature of hMSCs. It is estimated that a therapeutic
dose of 106 to 15x106 stem cells per kilogram are needed to treat diseases such as diabetes
and myocardial infarction.6–9 These high estimates are due to apoptosis, unwanted
differentiation, and cell attrition after implantation.10–12 Furthermore, dosing strategies
may require multiple doses, further inflating estimates. This may explain the lack of
phase three clinical trials.12 Scaled bioproduction of hMSCs is one way to supply such a
large number of stem cells. However, conventional scalable culture procedures are
difficult since hMSCs are anchorage dependent and sensitive to mechanical and chemical
stresses.13–15 Exposure to high shear stress, media gradients, unfavorable surface
treatments, improper cytokine mixtures, or nanotopologies can lead to differentiation and
apoptosis.15–18 In scalable systems aimed at producing hMSCs, any of these factors would
decrease purity and result in lost yield. Per the International Society for Cellular Therapy
(ISCT), tested stem cell populations must be greater than 95% positive for CD105, CD73,
and CD90, while being negative (less than 2% positive) for CD45, CD34, CD19 and
CD14 via flow cytometry in order to be considered pure.19 hMSCs must also maintain
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their ability to differentiation into adipocytes, chondrocytes, and osteocytes. Any
decrease in purity would increase downstream purification, further decreasing cell yield
and increasing cost.
To meet the high hMSC yields and purities needed, specialized bioreactors have been
developed to optimize culture conditions. Systems used for stem cell bioprocessing vary
but fall into three general categories: stacked two-dimensional surfaces, microcarrier or
aggregate based, and fixed bed reactors. A brief comparison of various adherent cell
culture methods can be seen in Table 4-1. Stacked systems such as the Xpansion
Multiplate parallel plate bioreactor (Pall) combine multiple 2D culture surfaces into one
unit analogous to multiple T-flasks.20 Media can then be flowed laterally across the cells
to supply nutrients and exchange gases. Though the most similar to flask culture, it is
difficult to visualize for in-process tests and may produce more shear than desired.21,22
Microcarriers have been used for 3D suspension culture of adherent stem cells. They can
be made from a variety of materials including inorganic plastics, sugars, and digestible
materials.12,23,24 The microcarriers are suspended via mechanical mixing while cells
adhere to the surface of the microcarriers. Because mixing is usually impeller driven,
cells can be exposed to high shear.22,25 Using microcarriers also involves more
downstream processes to purify the cells from the carriers, and lifting procedures can
involve multiple steps.7,26 Fixed bed reactors use fiber mesh as their culture surface and
provide nutrient and gas exchange by flowing media through the mesh. Examples of this
type of bioreactor include the iCELLis (Pall), hollow fiber membranes such as Quantum
(Terumo BCT), and the Express (Sepragen) reactor. Like the multiplate systems
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mentioned, it is difficult to visualize the cells during culture. A summary of cell yield and
reported values of various cell culture systems can be seen in Table 4-2.
Here we investigate a scaled down model of the Express bioreactor. The variant tested
works much like the parent reactor, using gravity and wicking of media to provide
nutrients and gas exchange to a growth matrix suspended above culture media. This
geometry and media circulation strategy results in low shear fluid movement. Instead of
cellulosic, a 3D printed lattice made of Polylactic Acid (PLA) lattice matrix is suspended
outside of the liquid media, providing a biocompatible culture surface with similar
stiffness to plastics used in conventional culture. Small sampling shelves are integrated
into the lattice matrix, which can be easily removed for cell sampling and imaging. By
combining this dynamic culture method with a hypoxic conditioning, stem cell
proliferation was significantly increased while maintaining stem cell biomarker
expression.

4.3 METHODS
Stem cell culture
hMSCs were cultured according to guidelines provided from American Type Culture
Collection (ATCC). Briefly, cells were cultured in hMSC media (ATCC PCS-500-030)
supplemented with the bone marrow derived hMSC bullet kit (ATCC PCS-500-041) at
37°C and 5% CO2 on T-75 treated tissue culture flasks. A ¾ media exchange was
performed on day 3, and cells were passaged at 80% confluency, usually on days 6 or 7.
Cells were lifted using 3.5mL of 0.25% trypsin and 0.53 mM EDTA solution (ATCC 302101) for regular passaging of T-75 flasks, and cells were re-plated at 5,000 cm-2. Cell
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pelleting was performed by centrifugation at 270 x g for 5 minutes. Working cell bank
was created from passage 4 hMSCs and stored in liquid nitrogen. Experiments using
hMSCs were conducted on cells between passage 5 and 9. Specific growth rate and
doubling time were calculated to compare culture success.
𝑇𝑑 = (𝑇2 − 𝑇1 ) ∗

ln(2)
𝑞
ln (𝑞2 )
1

Equation 4-1: Doubling time. Where Td is the doubling time in days, q2 is the final cell count, and q1 is the
initial cell seeding quantity.

𝜇=

𝑞
ln (𝑞2 )
1

𝑡

Equation 4-2: Specific growth rate. Where μ is the specific growth rate in hours, q2 is the final cell yield
and q1 is the initial cell seeding quantity.

Oxygen tension studies
To induce low oxygen states, cells were placed in a hypoxia chamber (billupsrothenberg) and gas flushed for 6 minutes with the regulator set at 5PSI and 10L min-1.
Gas composition varied but was mixed based on PSI. For reactor cultures the mixed
gasses were introduced at 100mL min-1 for 5 minutes to exchange the head space and
oxygen from the media. At first tri-gas mixture including 5% CO2 was used, but hMSCs
preferred basic conditions and as such CO2was excluded from later bioreactor runs with
negligible impact on yield and purity.

Reactor construction
The chamber of the reactor is made of a 9cm long polycarbonate tube with an ID of
2.25in and an OD of 2.50in. Four 316 stainless steel barbed hose adapters are tapped into
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the top of the polycarbonate, two for media circulation and two for gas exchange through
0.2µm filters. Size 14 silicone hose was used for main liquid handing loop, with a Tygon
Pharmed section for peristaltic pumping. The headplate and backplate are made of 316
Stainless steel. The interior reactor components include the 3D printed matrix, which is
suspended out of the media using two brackets. Media pumped to the top of the lattice is
perfused through the lattice design via gravity, providing gas exchange and nutrients to
the cells. Gas control is highly tunable, as there is less liquid for gas to diffuse through to
be available to the cells. The front plate of steel has a pass-through port for access to
removable sampling scaffolds to monitor cell confluency. Both the lattice matrix and the
holding parts were printed from PLA. Minimum and maximum working volumes used
were 20 and 30mL.

Lattice design and bioreactor culture
PLA matrices were 3D printed using a PrintrBot Simple printer and Cura 3D (V3.2.1)
printing software. A 0.4mm nozzle diameter was used. PLA was chosen as it has been
used for cell culture, is both biocompatible and biodegradable, and is a thermoplastic
commonly used in 3D printing.27,28 The lattice is constructed in such a way that the
smallest features are printable with a conventional 3D printer, and allow ample space for
cells to culture into monolayers. For this extruder the lower limit of resolution was 400
microns in the XY plane. The lumen between fibers was made to be the same width as
the fiber itself. Also included into the design are two inserts for non-destructive means of
visualization of cell confluence and viability via calcein staining. To sterilize parts before
culture, the matrix and supports are assembled and placed into reactor and steam
sterilized at 121°C for 15 minutes under a dry cycle. After sterilization the matrix is
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washed and wetted with filtered and autoclave-sterilized 1x PBS (VWR VE404) and
gelatinized with filtered and autoclave-sterilized 0.1% (W/V) gelatin (Fisher 9000-70-8)
in MQ water for 45 minutes at 37°C, or overnight at 4°C. The matrix is then rinsed with
PBS to remove excess gelatin, and cells are seeded at 2,500 cells cm-2. Approximate
surface area was calculated using Solidworks (Waltham, MA) analysis function. To allow
cells to adhere only in the lattice the desired number of cells were resuspended first in a
total of 2mL, as this volume was found to be the holding volume of the matrix. Cells
were allowed to settle in the matrix for 45 minutes before starting the recirculation loop.
Recirculation was run between 0.25mL min-1 and 0.5mL min-1. A range is noted because
as the peristaltic tube relaxed during use, the peristaltic pump tended to speed up, slightly
increasing the overall rate. This was the allowable flow rate range because it was the
slowest rate that still allowed complete matrix wetting. A ¾ media exchange was
performed on day 3, and cells were harvested on day 7 using a lifting cocktail comprised
of a 2:1 mixture of Cell Dissociation Buffer (CDB) (Gibco 13151014) and TrypLEExpress (Gibco 12604021). Lifting was accomplished by aspirating media out and
cycling 10mL of PBS through system at 1ml min-1 to remove residual media. PBS was
then aspirated and cell lifting cocktail was added. The reactor was then cycled at 0.25ml
min-1 for 30 minutes, or later at 1.5mL min-1 for 15 minutes. Viability and cell counting
were performed using hemocytometer and trypan blue staining.

Microcarrier culture in spinner flask
Cytodex-1 microcarriers were weighed and autoclaved at 121°C for 15 minutes.
Microcarriers were then hydrated in hMSC media. Cells were seeded at 5,000 cells cm-2
in 50mL of media in a 250mL spinner flask (Wheaton). For the first 24 hours, the spinner
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flask was set to 15RPM to allow hMSCs time to adhere to the microcarriers, after which
agitation was increased to 30RPM and volume increased to 80mL. A ½ media change
was performed on day 3. Samples were drawn each day and fixed in 4%
paraformaldehyde (PFA) for 15 minutes. Cells were then prepared for cell counting via
DRAQ5 (Abcam ab108410), staining in a 5mMol solution overnight. Samples were then
washed twice with PBS, allowing microcarriers to gravity settle between washes.
Samples were imaged on Leica SP5. The culture was run for a total of 7 days. On day 7
media containing microcarriers was split into 50 falcon tubes and microcarriers allowed
to settle for 20 minutes. Media was aspirated and microcarriers washed twice with PBS.
When settled again, TryplE (Gibco 12604021) was added and mixture was put back into
the incubator for one hour to lift cells for counting and characterization.

Confocal microscopy
Cells were cultured on lattice matrices in the bioreactor for seven days. Cells were
washed using Ca++ and Mg++ PBS and fixed in place with 4% PFA for 15 minutes and
washed again with PBS. Permeabilization was performed using 1% (W/V) Triton-X 100
in PBS for 30 minutes at 37°C. Cells were then washed and placed in 1% (W/V) Bovine
Serum Albumin (BSA) and 0.1% (W/V) Triton-X 100 in PBS for one hour at room
temperature. Cells were then stained for 30 minutes with 1 drop mL-1 Phalloidin green
(Invitrogen) and 1µl mL-1 DRAQ 5 (Abcam) resulting in a 5mMol solution in the
blocking solution. Cells were washed with Ca++ and Mg++ PBS and imaged on a Leica
SP5 confocal microscope.
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SEM imaging
PLA matrices were washed and prepared for electron microscopy. Samples were stuck to
0.5in slotted stages (TED PELLA 16111) using conductive double-sided copper tape.
Samples were imaged at 2kV using Hitachi SU-70 scanning electron microscope.

Flow cytometry
hMSCs were cultured in experimental conditions and lifted with a 2:1 mixture of Cell
Dissociation Buffer (CDB) (Gibco 13151014) and TrypLE-Express (Gibco 12604021)
lifting cocktail to preserve cell surface markers. Cells were washed in PBS and placed in
lifting cocktail for 15 minutes. After neutralization with fresh media, cells were fixed in
4% PFA for 15 minutes, washed twice with PBS, and blocked for 1 hour at room
temperature. Blocking solution consisted of 1% (W/V) BSA (LONZA) and 0.1% (W/V)
Triton-X 100 in PBS. Cells were stained for the positive markers CD105 (Invitrogen
MHCD10520) and CD73 (Abcam ab157335) and were negative markers CD14 (Abcam
ab91146) and CD19 (Abcam ab25510) at 1μL per 500,000 cells in 500μL following
recommendations. Samples were then run at medium speed (35μl/min) on a BD Accuri
C6 flow cytometer and analyzed using FlowJo (Ashland, OR). Unstained controls were
used to gate cells. Fluorophore compensation was done through FlowJo and Fluorescence
minus one (FMO) techniques.

hMSC Differentiation and staining
For both adipocyte and osteocyte differentiation, hMSCs were seeded at 12,000 cells cm2
and cultured for three days in hMSC media following ATCC Toolkit protocols. ATCC
differentiation toolkits for Osteocyte (PCS-500-052) and Adipocyte (PCS-500-050)
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differentiation were used. On the third day media was completely exchanged. For
Adipocyte differentiation a conditioning pre-differentiation media was used, and every
third day a ½ media change was performed with Adipocyte maintenance media.
Osteocyte differentiation did not require a conditioning media and was maintained with
only osteocyte toolkit media. On day 20 cells were washed with calcium magnesium free
PBS and fixed by 4% PFA at room temperature for 15 minutes. Cells were washed,
stained following respective protocols explained below, washed with MQ water, and
visualized on a phase contrast Olympus IX microscope.
Chondrocyte induction was performed according to a combination of ATCC protocols
and previous research. Briefly, hMSCs were lifted from reactor using lifting cocktail, and
counted. Cells were resuspended in chondrocyte differentiation toolkit (ATCC PCS-500051) at 125,000 cells mL-1. 200µl of cell laden media was put into 15ml polypropylene
falcon tubes and centrifuged at 270 x g for 5 minutes and placed into incubator without
resuspending cell pellet. When placed into incubator the tops of the tubes were loosened
to allow gas exchange. After 24 hours the pellet was gently suspended via pipetting.
Media was changed every 3 days for 21 days total. On day 21 cell aggregates were sliced
into 8µm thick samples using a HM 500 cryostat (Microm) and OTC compound (Tissue
Tek 4583) and place onto glass slides. Samples were then stained and visualized on a
phase contrast Olympus IX microscope.

4.3.9.1 Oil red O
Oil Red O was used to stain adipogenic differentiation of hMSCs. A working solution
was prepared by mixing 3ml of Oil Red solution (#O-1391, Sigma) 2ml of MQ water
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immediately before. Cells were covered with oil red working solution and stained for 30
minutes at room temperature. Cells were washed twice with MQ water and visualized.

4.3.9.2 Alizarin red
Alizarin Red stain was used to stain osteogenic differentiation of hMSCs. It arrived in
working concentration at the proper pH, so no extra formulation was necessary. After
fixation cells were washed twice with MQ water, then Alizarin red staining was overlaid
onto the cells and left for 15 minutes. Cells were then washed three times with MQ Water
and visualized.

4.3.9.3 Alcian blue
Alcian blue was used to stain for chondrogenic differentiation of hMSCs. After cryostat
slicing the samples were washed in Ca++ Mg++ PBS to preserve attachments while
removing OTC compound, and fixed for 15 minutes in 4% PFA. The slides were then
washed gently in DI water and alcian blue stain was overlaid onto the samples for 30
minutes. After 30 minutes the slides were rinsed with DI water, and then washed with 3%
(V/V) glacial acetic acid solution in MQ water to remove excess dye. The cells were then
gently rinsed again with DI water and visualized.

Computational fluid dynamic modeling
A simplified model was created in ANSYS 8.1 using a multiphase Volume of Fluid
model in ANSYS FLUENT 18.2 (ANSYS Inc., Canonsburg, PA). The model consists of
an inlet, the lattice made of crossing 0.4mm square flow channels, a center void where
the lattice would be anchored to its support in the system, and an outlet. The object was
meshed with 28,530 quadrilateral elements. Viscosity was modeled using Naiver-stokes
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equations and simulated using Standard K epsilon. Both energy and species transport
were included. The SIMPLE pressure-velocity coupling scheme was used to run a
transient model. Momentum convergence was set to 10-8. The inlet velocity was
calculated by taking volumetric flow and dividing it by the diameter of the simulated inlet
to give velocity. The model was validated comparing velocity in the model to dye
experiments. Shear stress was calculated by equation 3 using reported strain rate.

𝜏 = η𝛾

Equation 4-3: Shear Stress. Where τ is the shear stress in dynes cm-2, γ is the strain rate (s-1), and
η is the viscosity of the liquid in dynes cm-2.

This value was used in conjunction with the lowest flow rate needed to keep the lattice
wetted.

Statistics
Graphs and statistics were done using Minitab 17 (Minitab Inc., PA). Error bars on
graphs show 2 standard errors. Student's two‐tailed t‐test was used to determine
significance for two data sets. Significance of multiple data sets was performed via oneway ANOVA and Tukey test.

4.4 RESULTS
Scaled System
The aim of this work was to show high purity, high yield stem cell culture on a 3D
biocompatible lattice. To do this a scaled model of the system of the Express bioreactor
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was engineered, conserving the main geometry of the reactor chamber and method of
media handling. PLA was used in leu of cellulosic, as cells tended to grow in clusters on
cellulosic fibers (data not shown). To accommodate the PLA in an unobtrusive way, two
stands were also made using 3D printing. To decrease shear from the falling water
droplet, a 316 stainless steel tip was added to allow seamless flow from the recirculation
loop to the lattice growth matrix. The full reactor assembly and photo of the system can
be seen in Figure 4-1. As an easy means of visualizing cells, sampling shelves were built
into the lattice. This allowed for simple sample harvest and preparation for fluorescent
microscopy. This sample shelf was constructed in the same geometry as the lattice itself.
From 3D modeling in Solidworks it was calculated that the 30mm diameter lattice used
has a theoretical surface area of 225cm2. As a comparison, each 30mm diameter
repeating layer provides 23.5cm2, which equates to a 32-fold increase in surface area
when comparing the 3D lattice to the equivalent 2D culture area.
CFD Modeling
To demonstrate the principle of the reactor and extrapolate hydrodynamic forces in the
lattice, ANSYS FLUENT was used with a simplified model of the growth lattice. SEM
images (Figure 4-2) of the scaffold were taken to understand the printed geometries and
properly model the system in FLUENT (Figure 4-3). A dye tracer benchtop experiment
was used to validate the model. As mentioned, media is cycled to the top of the circular
lattice and pulled by gravity through the pores. Because mixing is accomplished through
passive means rather than an impeller, the system is inherently very low shear. This was
proven by testing a range of flow rates to estimate shear vs flow rate (Figure 4-4). All
prospective flow rates fell well below 0.4 dynes cm-2. As 0.25mL min-1 resulted in the
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lowest shear while keeping the matrix well wetted, it was the tested flow rate for hMSC
culture. At this flow rate CFD modeling reported a maximum of 0.0054 dynes cm-2
(Figure 4-3) and an average of 0.00031 dynes cm-2 (Figure 4-4). The areas of highest
shear were at the top and bottom center of the matrix insert, where the media was
entering and exiting the lattice respectively.
Spinner flask control
As a comparison hMSCs growth was also investigated on Cytodex-1 microcarriers in
small scale spinner flasks. Static cultures (n=6) showed an average doubling time and
specific growth rate of 119.07hrs ±11.23 and 0.0062 hr-1 ±0.0013 respectively (Figure
4-5 A). Cells cultured in spinner flasks showed an average doubling time of 113.6hrs
±23.75 and a specific growth rate of 0.0062hr-1 ±0.0013 (n=3) (Figure 4-5 B). Both are
significantly longer (p=0.002) compared to lattice reactor (n=5) results, which are
discussed later.
Cell viability on PLA Lattice
Cell viability was compared between culture substrates and static vs dynamic cultures as
previous studies with fibrous matrices exhibited increased cytotoxicity. On day 7 of
cultures, cells were enzymatically lifted and viability was tested via trypan blue staining.
PLA lattices were removed from culture wells to isolate only cells adherent to the PLA
lattice. Dynamic PLA cultures from the bioreactor had an average viability of 96.54%
±2.82. Cells grown in dynamic bioreactor culture on PLA showed no statistically
significant difference (p=0.98) from static PLA culture plates, with an average viability
of 96.76% ±3.84. Dynamic PLA showed no difference (p=0.45) from Static PS, which
had an average viability of 95.13% ±1.07. This is also in agreement with the fact that
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static PLA and PS showed no statistical difference in viability (p=0.38). Therefore, PLA
showed no detrimental effects on cell viability in both static and dynamic cultures
compared to conventual culture on treated polystyrene flasks.
Dynamic seeding
Because of the larger channel sized and homogeneity of the lattice, a new seeding
protocol was developed to increase seeding efficiency. The method that yielded the best
results was through static settling of the cells. The volume of media the lattice could hold
was found to be 2mL. Thus, 500,000 cells were resuspended in 2mL of hMSC media.
This cell rich media was then slowly injected through a Luer lock until liquid had cleared
the lines. The reactor was then placed into the incubator for 45 minutes to allow cells to
settle onto lattice and adhere. Hypoxic gas was then overlaid into the system though the
filter ports and the peristaltic pump was then started. Cells formed confluent monolayers
towards the top center of the lattice sampling shelf (Figure 4-6).
Reactor Culture
Normoxic reactor culture resulted very similar doubling time as PS control cultures
(Figure 4-7 A). Because hMSCs normally grow in more comparatively more hypoxic
conditions in vivo, oxygen tension was investigated as a means of increasing cell
proliferation. It was found that 1.5% O2 resulted in a four-fold increase in cell yield;
double that of conventional flask culture methods tested (p<0.001) (Figure 4-7 B).
Normalized yield to surface area was 13,725 cells cm-2 at 1.5% O2 (Figure 4-7 C).This insitu conditioning resulted in the significant increase in specific growth rate (O.0085hr-1
±0.0005) (Figure 4-7 D). When lifted and analyzed via flow cytometry it was found that
cells cultured in the bioreactor retained their biomarker phenotype regardless of gas
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composition used for hypoxic treatment (CD105+ CD73+ CD14- CD19-); ANOVA
showed no significant difference in CD105 (p=0.309), CD73 (p=0.347), CD19 (p=0.676),
and CD14 (p=0.523) biomarker expression (Figure 4-8). Thus, oxygen tension had a
drastic effect on cell proliferation, and no effect on biomarker profile. Cultures primed at
0% and 1% (n=3 for both conditions) produced statistically similar cell yields, and
cultures primed at 5% and 21% oxygen showed no statistically significant difference via
Tukey test at 95% CI. Compared to control cultures on static tissue treated PS, the
dynamic bioreactor culture on PLA produced a higher purity MSCs according to ISCT
standards, Lifted cells were over 98% dual CD105 and CD73 positive cells in reactor
culture compared to 94% in static normoxic polystyrene culture (p=0.005) (Figure 4-9
A). There was no significant difference in the negative markers CD14 and CD19 under
normoxic (n=9) or 1.5% hypoxic conditioning (n=6) (Figure 4-9 A), and single
populations of cells were harvested from bioreactors (Figure 4-9 B). Again, cells formed
monolayers on the PLA filaments much like control cultures on PS dishes (Figure 4-6).
Differentiation potential
As previously discussed, ISCT standards for stem cell purity and identification include
differentiation ability. To test stemness, osteocyte, adipocyte, and chondrocyte inductions
were performed stem cells harvested from seven-day bioreactor culture. For inductions
cells were cultured between 15 to 20 days in their respective, defined ATCC
differentiation media, after which cells were washed, fixed and stained. After seven days
in bioreactor culture and hypoxic conditioning the cells retained their ability to
differentiate into Adipocytes, Chondrocytes, and Osteocytes (Figure 4-10). Control
cultures were also done in parallel with the inductions and stained with the same dyes.
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Control cultures showed no staining of uninduced cells cultured for 21 days in hMSC
media.

4.5 DISCUSSION
By culturing hMSCs in this scaled down bioreactor, we were able to increase cell yield
four-fold over conventional flask culture methods. It was found that cells cultured in this
manner maintained high expression (>97% combined CD105+ and CD73+) of positive
stem cell markers. PLA did not impact cell viability compared to cultures on polystyrene
in both static and dynamic culture conditions. CFD modeling shows very low velocities,
and subsequently low shear inside the lattice matrix. The computational modeling of this
lattice reactor reports maximum values of 0.0054 dynes cm-2 (Figure 4-3). CFD of stirred
tank reactors utilizing microcarriers report values of approximately 1 to 5 dynes cm-2, and
packed bed Fibracell systems report an average shear of dynes cm-2 (Table 4-2). Tubular
systems with similar laminar flow patterns report average values of 0.98 dynes cm-2.29
These values all fall within 0.02 to 9 dynes cm-2, a range shown to upregulate osteogenic
genes and differentiation in hMSCs.15,30,31 The system tested at the parameters
determined was two orders of magnitude lower than this reference range.
Surface profile of hMSCs did not change with oxygen percentage, as ranges tested were
within physiological normoxia and treatment times were comparatively short to other
hypoxic culturing.32 These findings follow previous findings of oxygen tension
promoting stem cell proliferation and stemness.33–36 As mentioned previously, cells were
most concentrated on the top of the fibers. In reality, the cells seem to utilize only the top
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portion of the fibers, which would be a product of their static seeding. This would make
cell-seeding density closer to 5,000 cells cm-2.
This combination of hypoxic conditioning and gentle fluid movement may be mimicking
their niche more closely than static cultures. PLA printed by filament deposition has a
modulus of elasticity of 3.2, which falls in the range of elasticity of trabecular bone.37,38
BM-hMSCs are normally harvested from the trabeculae of the iliac crest or head of the
femur. When these three factors are combined, it creates the normal niche for these stem
cells, which would explain why the cells perform much better in the dynamic culture
condition of the reactor compared to static flask culture.
As a benchmark, hMSCs were cultured on Cytodex 1 microcarriers. The doubling time
for this cell line grown in spinner flasks was significantly longer compared to culture in
the lattice reactor. Cells were not characterized via flow cytometry, as even after an hour
in TrypLE they did not lift from the Cytodex 1 beads. This problem of inadequate cell
lifting has been noted before.26 Whereas cells cultured in this system had no issue
dissociating from matrix using CDB and TrypLE.
Another benefit of this system is the comparative ease of downstream purification
compared to microcarriers. Microcarrier base culture of stem cells requires extra steps to
purifying the cells from the beads. Some beads require cell detachment using trypsin,
resulting in an extra step of straining the microcarriers from the lifted cells. Some
microcarriers are themselves digested by enzymes, eliminating the need of straining or
filtering. However, depending on the enzyme cell-cell junction may remain, resulting in
cell clusters in final product. Furthermore, the byproducts of digestion of these
microcarriers is still a concern for final formulation and patient administration.39 Per UPS
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<788> removal of microcarriers as particulate matter is recommendation for injected
products.7 Thus systems using microcarriers for hMSC therapies would require either
inertial steps or straining and filtration steps to remove microcarriers from cells after
dissociation, adding complication and potentially decreasing overall yield through
shear.40,41 Centrifugation of the cells can cause cell clumping and exposes the cells to
high shear, resulting in product loss.12 Also, filtration and straining have been shown to
decrease viability of harvested cells.41 In our system this purification step is more robust,
as cells can be washed in place and lifted with a reduced process related impurities after
lifting. By using recombinant TrypLE we have shown optimal cell lifting within 15
minutes. Another avenue of cell lifting in this system is via thermoresponsive polymers.
P(NIPAM) could be coated into the stationary PLA lattice, and cell lifting would be
completed by only dropping the temperature.42 This would eliminate the need for
exogenous enzymes and washes, easing downstream processes and subsequently
increasing yield. Unlike particulate from microcarriers, the degradation product of the
PLA lattice dissolves into solution as lactic acid.43 This byproduct can easily be removed
through buffer exchange, but it is also biocompatible and broken down in the body
naturally.
Because of its biocompatibility, cell detachment may not be necessary depending on the
application. As PLA is biocompatible and similar in rigidity to cancellous bone, hMSCs
can be expanded and differentiated in-situ. Polymer rigidity can be either avoided or
exploited for tailored stem cell differentiation. Harder polymers like PLA, polystyrene, or
polycarbonate (PC) can be printed using high temperature 3D printers, and can be easily
treated for cell adhesion. Softer, more elastic materials like polyurethane have been used
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for stem cell culture and are also readily available materials for 3D printing.44 Culture on
more elastic scaffolds, such as alginate encapsulation, can direct hMSCs to differentiate
into chondrocytes and has been used in established differentiation protocols45,46
Here we have shown a system for high purity stem cell culture. The system resulted in
above normal yields for tested systems, while maintaining high expression of stem cell
biomarkers. The cells lifted from the system were easily dissociated with minimal openair steps and required no extra purification. When tested for stemness, the cells readily
differentiated into osteocytes and were able to differentiate into adipocytes.
Another possible use of this system is for the production of secreted product, as cells are
adherent to a stationary scaffold. This system is ideal for secreted proteins and vesicles.
The cells are bound to the substrate and will release cytokines and exosomes of
therapeutic interest into circulating media. Research into exosomes has shown their
usefulness in wound healing and inflammatory diseases.47–49 These vesicles are secreted
by hMSCs and contain mRNA, cytokines, growth factors, and other signaling molecules
involved in healing, and are a major interest for regenerative medicine.49 The proposed
lattice system can be run in perfusion, allowing simple harvest of the secretome while
cells are held stationary in the reactor.

4.6 CONCLUSION
Here we show the successful use of a scale down model of a novel suspended matrix
bioreactor for the culture of hMSCs. Cells adhered well to PLA lattice and grew as
monolayers similar to conventional culture techniques. A combinatory effect of low
oxygen tension and slow recirculation rate of 0.25mL min-1 through the lattice based
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culture resulted in higher than average cell yields compared to conventional expansion
systems, including static T-flasks and spinner flask with microcarriers. 1.5% O2 gas had
the best cell growth, resulting in a four-fold increase in overall cell yield. The cells lifted
from the reactor showed excellent stem cell biomarker expression through flow
cytometry, showing significant increase over conventional flask culture. hMSCs also
retained their ability to differentiate into bone, cartilage, and fat cells. Further work into
scaling this system up needs further investigation. Nonetheless we have shown the
validity of suspended matrix reactor systems for high purity hMSC production.
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Table 4-1: Reactor Advantages and Disadvantages for hMSC Culture. Adapted from Liu et al.23 and Kumar
and Starly.43
Type
Microcarrier

Plate

Packed bed

Advantages

Disadvantages

Support high-density cell culture; regulate
cell growth and differentiation; serve as
cell delivery systems. Easy to scale up.
Easy sampling and cell visualization

Difficult to harvest cells. Purification from
microcarriers. Still some possible shear
issues due to energy required for
suspension. Limited growth area on
microcarriers.

Very similar to flask culture; easy to
translate. Low shear stress because no
impellor needed

Difficult to visualize cells. environment is
inhomogeneous due to the nutrient and
oxygen gradient

Provide 3D microenvironment; allow cell
spatial organization; regulate
proliferation, differentiation and tissue
formation. Large SA:V

Difficult to harvest cells. Difficult to
visualize cells. Concentration gradients.
Indirect cell measurements
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Table 4-2: Comparison of Culture Systems. Volume, available surfaces areas, cell types used, total stem cell yield normalized to volume and surface area, total
overall yield, doubling time and reported shear rates of various systems.
Name
Quantum

Type
PDMS
Matrix
Hollow
Fiber

Classification

Vendor

V
(mL)

SA
(cm2)

SA:
V

Immobilized

-

110

2,800

25.5

1,440

21,000

14.6

50,000

300,000

6

Immobilized

TERUMO
BCT
Milipore
Sigma

Cell
type
hPMSC
hAdMSC
hBMMSC
hAdMSC
hBMMSC

SC/mL
x106

SC/cm2
x104

Tota
l SCs
x106

Td
(hr-1)

Shear
(dynes
cm-2)

Source

0.509

2.00

56

30.2

1-5

44

0.167

1.14

240

34.1

0.3-0.7

45–48

2.00

1.67

5,00
0

54.0

2-40

46,49,50

0.190

3.87

285

31.2

0.1-0.5

5,51

1.90

-

5,70
0

63.0

-

52

0.1-0.5

18

1-5

50,53,54

0.0048

-

Mobius

STBR

Suspension

Applifle
x

Wave
Bag

Suspension

Applikon

1,500

7,360

4.91

Mag 3

Paddle

Suspension

PBS

3,000

-

-

Xpansio
n
Multiplat
e

Parallel
Plate

Immobilized

Pall

1600

6,120

3.83

hAdMSC

0.111

5.4

334

34.1

iCellis

Random
Fiber
Matrix

Immobilized

Pall

1000 5000

40,000

40

hBMMSC

2.93

16

-

67.2

In House

Lattice

Immobilized

-

20

122

6.1

hBMMSC

0.2

2

1.8

82
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Figure 4-1: Schematic and picture of reactor. A) Exploded diagram of components and how they are
pieced together. B) Image of assembled reactor. C) Cartoon front-on schematic of how lattice is suspended
out of media and fluid is recirculated through system.
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A

B

C

D

E

F

Figure 4-2: Scanning Electron Microscopy images of 3D Printed PLA. A) Outside side orientation. B) Cut
interior orientation. C) Top down view of PLA lattice. E) High zoom of Outside side F) Cut interior, and G)
top-down views. Red red squares denote zoom seen in second row.
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Figure 4-3: CFD modeling of lattice matrix. A) Velocity contour and B) shear stress. Maximum velocity of
0.0039m s-1 and maximum shear stress of 0.0056 dyne s cm-2 measured inside the lattice, excluding the inlet
and outlet. Shear was calculated by multiplying strain rate by the viscosity of the fluid.
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Figure 4-4: Inlet Flow Rate vs Average Wall Shear. The lattice matrix was modeled in ANSYS and tested at
various flow rates using Fluent. Strain rate was converted into shear stress using Equation 4-3.

116

DocuSign Envelope ID: 9BFE76AE-08BD-4F0D-906A-66E514EAA4DB

Figure 4-5: Culture method on A) doubling time and B) specific growth rate of hMSCs. Static cultures
grown in t75 flasks according to ATCC guidelines. Spinner cultures used Cytodex-1 microcarriers in
spinner flask. Dynamic culture used PLA lattice as per method
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Figure 4-6: hMSCs imaged on PLA Scaffold from bioreactor. Cells underwent a three-day prime at 1.5%
oxygen and were then cultured out for seven days. Stained with phalloidin (red) and DRAQ5 (blue). A) and
B) show hMSC on single fiber. C) Low magnification showing hMSC coverage among parallel fibers. D)
Projected Z-stack of fibers showing cell coverage. Center image shows top view (XY projection). Top and
side bars show sideways projection (ZX and ZY)
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A

B
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D

Figure 4-7: hMSC bioreactor culture of varying oxygen tension compared to static culture of same oxygen
amounts harvested on day 7. A) Doubling time, B) Fold increase, C) Cells per cm 2 D) Specific growth rate,
and doubling times of hMSC. Day seven cell harvested from reactors
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Surface Marker Characterization of Lattice Bioreactor Culture
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Figure 4-8: Flow Cytometry of hMSC from Reactors harvested Day seven from varying oxygen tension.
CD105, CD73, CD19 and CD14 stained cells were analyzed using flow cytometry. No significant
difference was found in marker expression vs hypoxic preconditioning.
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Figure 4-9: hMSC biomarker characterization using flow cytometry. Cells were cultured in both static and
in bioreactor and compared using CD105, C73, CD19, and CD14 staining. B) Overlaid flow cytometry
image of 1.5% O2 primed hMSC cultures from D7 bioreactors.
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Figure 4-10: Stem Cell induction. Cells harvested day seven from bioreactor and cultured out in in
respective differentiation media following specialized protocols. After allotted time cells were fixed,
stained, and imaged using light microscopy. Scale bars are 100 microns.

122

DocuSign Envelope ID: 9BFE76AE-08BD-4F0D-906A-66E514EAA4DB

5 COMPUTATIONAL FLUID DYNAMICS
5.1 ABSTRACT
Computational Fluid Dynamics (CFD) is a method of modeling fluid flow and energy
transfer in silico. In bioprocessing this technique is used both to optimize and
characterize cell culture systems. In this study we use CFD to better understand
hydrodynamic forces and flow regimes within the lattice of the bioreactor. For this we
modeled flow in a 2D model of the scaffold insert of reactor. This was accomplished by
alternating 400µm by 400µm squares representing the cross sections of the polylactic
acid fibers. Alternating the fibers made the model match flow patterns seen in benchtop
dye experiments, bring 3D flow patterns into the 2D simulation. We found that laminar
flow through the channels of the PLA lattice is predicted to only produce a maximum of
8.0x10-4 dynes cm-2. We also calculated the KLa to be 2.14 hr-1, very similar to other unsparged culture vessels for stem cell bioproduction. This prediction confirms laboratory
testing of the system were sensitive cell types cultured well in the scaffold.

5.2 INTRODUCTION
In this work we use CFD and fluidic validation techniques to characterize a novel low
shear bioreactor for use with sensitive cell types. We accomplish this by using a
simplified model in ANSYS 18.2 Fluent and show that when run within certain
boundaries will provide an acceptable environment for the culture of human
Mesenchymal Stem Cells (hMSCs). This type of adult stem cell is found in many tissues,
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but is mainly sourced from adipose, bone marrow, or umbilical cord blood.1 hMSCs have
been shown to react to shear stresses, often differentiating into osteocytes and decreasing
overall stem cell yield when bioproducing this cell type for regenerative medicine.2 Thus,
being able to model a system aimed at producing pure hMSCs as a product allows
researchers to characterize the shear stresses the cells may be exposed too, moving design
from long and expensive benchtop studies to relatively faster and cheaper in silico
modeling.
CFD is a field of applied mathematics aimed at computing fluid flow and forces. CFD
works by numerically calculating fluid flow and resulting forces. It does this by solving
Navier-Stokes equations for mass, momentum, and energy conservation. To accurately
and timely solve for these values the area of fluid flow is broken down into smaller
geometries called elemental volumes. The discretization of a geometry into elemental
volumes is a process known as meshing. The solver can then calculate desired equations
for these cells based on methods including Finite Difference Modeling (FDM), Finite
Volume Modeling (FVM), and Finite Element Modeling (FEM), with FEM being the
most common.3
CFD is a valuable tool for the characterization of bioreactor design and operation.4,5 does
not eliminate benchtop experiments, but it can decrease the amount of time and cost of
designing systems. It can also be used to characterize existing stir tank bioreactor
systems, with a common application being to test impeller speeds vs mixing and shear.6
CFD modeling for adherent stem cell bioreactors can be used to determine shear stress
where media flow can affect cells. In the system tested here it allows the user to
understand fluid flow patterns through a porous matrix. It can also be used as a means of
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ensuring that concept reactors will operate as intended, elucidating problem areas, such as
in concept reactors before mass production. It has also been very helpful in designing
scale models for cell culture, much like the system tested within.7,8 the ability to rapidly
test shear, mixing, pressure, and other parameters important in culture make CFD
modeling very useful when developing systems for sensitive cells, such as stem cells.
With regards to bioreactor culture specifically to these cells, CFD is invaluable for
quantifying how the geometry of the scaffold and supplementation of media impacts fluid
patterns and flow, velocity distribution and shear, as well as liquid mixing and related gas
transfer coefficients. As stated previously, CFD can also reduce the burden of benchtop
experiments, cutting cost of testing and increasing speed of development. All these
factors combined make CFD an ideal tool when developing and testing systems designed
to meet the high demand of biologically produced drugs and whole cell therapies.
The objective of this study was to utilize CFD to model fluid flow in the scaffold in a
similar fashion to other fixed bed systems.9 Flow regimes in such reactors are usually
lamiar due to the slow speed of media flow. Laminar flow is defined by Reynolds
Number (Re), where a system with a Re less than 2300 is considered laminar. For a pipe,
or through channels like in this system, a Re less than 1000 is laminar flow. This means
that there is no turbulence in the system and flow move steadily with little mixing. While
turbulence drives mixing in many systems, it is important with stem cells to keep strong
hydrodynamic forces to a minimum. To accomplish this, systems for stem cell culture
often operate at much slower flow rates, but this can lead to media gradients and low
oxygen diffusion. To compensate for this special geometries can be used to drive mixing
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in a way that does not increase the amount of shear the cells are exposed to. Reynolds
number though a pipe is calculated following the equation:

𝑅𝑒 =

𝜌𝑉𝑑
𝜂

Equation 5-1: Reynolds Number. Where ρ is the density of the fluid, V is the velocity of the fluid moving
through the pipe, d is the diameter of the pipe, and η is the viscosity of the fluid at a given temperature.

The oxygen transfer rate into the system is also a valuable tool to determine bioreactor
performance, usually reported as the transfer coefficient KLa. This value can be
calculated in CFD by modeling turbulence, or is some small cases through laminar
modeling.10,11 KLa is incredibly important for bioreactor culture. In most systems oxygen
is the limiting factor for cell growth.12 A system with higher KLa can provide more
oxygen to cells. It is because of this that constant KLa has become a standard value to use
when scaling systems, from clonal selection to large scale culture.13
Mass transfer regimes can also be calculated using CFD. Péclet number is a
dimensionless number and is the ratio of advection rate to the diffusion rate. Using Péclet
number one can deduce whether the movement of gasses and nutrients in the media are
diffusing through mechanical mixing via fluid flow, or through molecular diffusion.
Regarding mass transfer it is calculated by the equation:
𝑃𝑒 =

𝐿𝑢
= 𝑅𝑒𝐿 𝑆𝑐
𝐷

Equation 5-2: Péclet Number. Where L is the characteristic length, u is the local velocity and D is the mass
diffusion coefficient.
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Péclet Number is also the product of the Reynold number and the Schmitt number. In
water, the diffusion coefficient of air is 2.0x10-5cm s-1.14,15 Using this information the
Schmidt number can be obtained by:
𝑆𝑐 =

𝜇
𝜌𝐷

Equation 5-3: Schmidt Number. Where µ is the dynamic viscosity of the fluid, ρ is the density of the fluid,
and D is the mass diffusivity.

In our system the shear stress is a byproduct of the velocity gradient of the fluid flowing
parallel to a surface, and is a property of the viscosity of the fluid. Velocity will be slower
closer to the wall of a pipe, and faster towards the center. This leads to a velocity
gradient, and near the walls where shear is the highest known as the boundary layer.
Shear stress can be calculated from the strain rate following the equation:
𝜏 = 𝜂𝛾
Equation 5-4: Shear Stress. Where τ is the shear stress, γ is the strain rate, and η is the viscosity of the
liquid.

As strain rate in the system is calculated spatially, this accounts for the distance from the
walls of the lattice. Thus, a wholistic map of shear stress can be obtained using this
equation.

5.3 METHODS
Computer rendering and machining
Solidworks Computer Aided Design (CAD) software was used to generate three
dimensional designs of the bioreactor scaffold for in silico simulations and experimental
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studies. This allowed model with behavior of flow for multiple geometries to optimize
both scaffold and reactor designs prior to 3D printing and machining. The scaffold,
comprising of fibers forming a homogenous lattice, was then 3D printed in PLA using
Printrbot Simple Metal printer.
The reactor tested here is a scaled system of the Express bioreactor manufactured by
Sepragen. To produce a quality model parts were modeled in Solidworks and physical
fits were tested via 3D printing, allowing easy design changes prior to machining the
system from stainless steel. After test fitting and addition of a sampling port and various
adapters the files were organized in Fusion 360 and milled on a CNC adapted Bridgeport
milling machine in 316 stainless steel.
ANSYS Modeling
A simplified 2D cross-sectional model of the scaffold geometry was rendered using
Design Modeler within ANSYS 18.1. A 2D model was used and was adequate to capture
the flow dynamics of the reactor due to the scale and repetition of the scaffold
geometries. The scaffold itself is comprised essentially of one unit that is repeated in a
lattice pattern. Designing the model like this reduced the computation time required while
providing and accurate characterization of fluid flow through the lattice. The scaffold was
prioritized, as it would be where the cells reside while culturing, and because it is the
narrowest point of the system and would theoretically result in the highest shear.
FLUENT was used to model fluid flow through the system. Turbulence was modeled
using k-epsilon in a VOF model using SIMPLE. Convergence was set to 10-8.
A 2D model was used to monitor tracer infiltration into the modeled lattice. The pressurevelocity coupling solution method used SIMPLE, gradient of lease squares cell based,
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pressure of PRESTO!, Second order upwind for momentum, geo reconstruct for volume
fraction, first order upwind for turbulent kinetic energy and for turbulent dissipation rate,
and second order upwind for energy. First order implicit was used for transient
formulation. A tracer with the same properties as water was modeled into the system.
After initialization the tracer was patched into the inlet and the simulation run for
simulated three minutes. This was chosen because of the time it took for dye to flow
through the entire system in the benchtop model.
Benchtop Dye testing
To validate CFD modeling the velocity and fluid movement was visualized using dye
flowing through the PLA scaffold. The lattice was first wetted with MilliQ water and set
up with the same nozzle as in the bioreactor. Fluid was handled via a peristaltic pump.
The media line above the inlet to the lattice matrix was teed to allow a pulse of waterbased dye into the loop. After the system had run long enough to purge air from the lines
and reach a steady state flow the pump was temporarily paused and the dye pushed into
the inlet until the color was seen beading on the tip of the inlet. The pump was then
reinitialized, and the matrix was filmed until it was saturated with color. Time points of
the video were then clipped and used as a visual comparison for CFD validation of
velocity and liquid movement.
Kla and Oxygen Transfer
To determine the coefficient of oxygen transfer of the bioreactor the system was filled
with 30mL of PBS and heated to 30°C and run at 0.5mL min-1. Pyroscience FireStingO2
dissolved oxygen (DO) system was used in conjunction with their small-scale flow
through sensor. Air was bubbled into the water inside the reactor until DO reading
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stabilized, at which point the probe was set to 100% DO. The media was then bubbled
with nitrogen to strip the system of oxygen until the reading stabilized, at which point the
probe was zeroed. Gas was pumped into the headspace for 3 minutes to strip nitrogen and
DO was measured over time. Oxygen percent [C] was correlated to concentrations and a
plot of ln(C*-C) vs time to obtain the KLa. The maximum Oxygen Transfer Rate was
then calculated using the equation:
𝑂𝑇𝑅 = 𝐾𝐿 𝑎(𝐶 ∗ ∗ 𝐶)
Equation 5-5: Oxygen Transfer Rate (OTR). Where OTR is in mMol O 2L-1 hr-1, KLa is the oxygen transfer
coefficient in hr-1, C*is maximum oxygen saturation of media at that given temperature and pressure in
mMol O2L-1, and C is recorded saturation. For OTRmax C is zero, making OTR a function of KLa and 100%
saturation of the media.

5.4 RESULTS
Early 2D modeling in CFD were not matching dye testing. The PLA lattice tested showed
good dye infiltration across the lattice insert, while initial models showed tracer moving
straight through. This was because when the geometry was converted to 2D, there were
direct channels for the fluid to move down, which was highly favored over horizontal
tracer movement. To fix this and better match the model to the fluid dye movement seen
in benchtop experiments, alternating fiber “holes” were patterned into the modeled 2D
lattice. This led to higher fidelity between the model and benchtop testing. The modeled
fibers were left as square due to the deposition method of printing. While the body of the
fibers are more rounded, there is compression of the layers at the joints, causing those
intersections to be more angular. This also helped to make meshing easier, resulting in a
more uniform mesh (Figure 5-1). Located halfway between the center and the top of the
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reactor are two rows of larger channels running horizontally. This is to mimic the gap left
in the lattice from the removable insert that resides there (Figure 5-2).
The simplified model agreed very well with actual tests at calculated equivalent flow rate.
The dye test in Figure 5-3 shows dye infiltration and dispersion in the model and the
tested scaffold. After model validation through dye testing Figure 5-3 a range of shear
values vs the flow rate of the pump was tested. Flow rates tested were between 0.125 and
1.00mL. Shear stress values in dynes cm-2 were calculated by multiplying the strain rate
by the viscosity of the fluid according to Equation 5-4. The calculated minimum and
maximum rates were 1.3x10-3 and 8.0x10-3 dynes cm-2. Average and maximum shear
values vs flow rates can be seen in Table 5-1.
The simplified model run at 0.25mL min-1 showed expected velocity profile through
fibers. Velocity was highest at the inlet and the outlet where fluid was concentrated. The
velocity slows as the lattice expands in the middle and the fluid disperses through many
channels. Strain rate mirrors the velocity profile (Figure 5-5).
By graphing the log difference in oxygen saturation of the media over time we were able
to calculate the KLa of the system to be 2.14hr-1 (Figure 5-6). From this OTRmax was
found to be 16.26mMol L-1 hr-1.
Flow was characterized as laminar by calculating Reynolds number. Using the average
fluid velocity of 0.000172m s-1 through a 0.4mm diameter opening the Reynolds number
was found to be 2.88x10-3 Via Equation 5-1. This indicates very laminar flow through the
channels of the PLA lattice. Average Péclet number in the channels was calculated and
found to be 21 via Equation 5-2. When horizontal velocity was used to calculate Péclet
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the result was 0.01, meaning that mass transfer within horizontal channels is mainly
through diffusion. Thus, mass transport of oxygen through the channels differ via the
direction. In vertical channels transport is driven though advection.
By using cell specific oxygen uptake rate, we can calculate under equilibrium what the
gas dependent maximum cell density achievable would be. Researchers report that bone
marrow derived hMSCs have a cell specific OUR of 9.8x10-11 mMol cell-1 hr-1.16

5.5 DISCUSSION
Initial flow rates were based on values found in literature, where researchers were
culturing shear sensitive mammalian cells in dynamic flowing system.17 All tested flow
rates resulted in shear values less than reported shear stresses shown to drive
differentiation in mesenchymal stem cells (0.02 -22 dynes cm-2)2,18 (Figure 5-4).
However, because shear is a source of impurities in cell yields the system was still
operated at the lowest feasible flow rate. This meant that the reactor was circulated at
0.25mL min-1, as it was the slowest rate that still wetted the surface of the lattice.
Velocity was high at the inlet because a fully developed fluid flow is entering narrowed
channels (Figure 5-5). The velocity quickly dissipates through the lattice as the fluid
becomes more dispersed through the structure. As these individual velocities begin to
combine in the bottom half of the reactor, we see fluid velocity begin to increase. This is
similar to other rigid lattice systems tested using similar fluidics modeling techniques.19
However, since fluid was moving freely though the system and not forcedly pumped
across the matrix, there is no pressure drop in this system and shear is comparably much
less in. As expected, strain rate mirrored velocity contours; shear was highest at the inlet
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and outlet of the matrix. However, even the maximum shear stress values within the
lattice where cells are attached fall well below reported values of 0.4-9 dynes cm-2 that
have resulted in stem cell differentiation.2 This is important as it has been shown that
exposure even as low as 0.02 dynes cm-2 can lead to upregulation of osteocyte markers.18
The calculated KLa is similar to the approximate 2.00hr-1 reported in stirred systems
using gas overlay without sparging.20,21 It is also within the range of 1.59-3.00hr-1
reported in a specialized system using gyroscopic mixing. 22 The lattice system tested
here also had higher KLa values compared to spinner flasks which, were reported to be
between 1.00-1.91hr-1.22 This rough similarity in KLa is likely due to the fact that gas
exchange in all of these systems is happening passively at the interface of the media and
the gas in the chamber. Since all methods mentioned are run with the intention of
decreasing shear, and consequently do not used forced oxygenation of the media, it is
reasonable that the KLa would be similar. It is also well above the reported KLa value
theoretically needed to sustain hMSC proliferation in a reactor.23
Using KLa we can calculate the theoretical maximum cell density. In steady state the
maximum oxygen transfer rate of the tested lattice system was calculated to be 16.264hr1

. Dividing this by cell specific OUR obtained from literature, we were able to determine

that gas exchange is not the limiting factor of the system. Furthermore, we can calculate
the theoretical maximum cell density. Using reported values, the maximum OTR of this
system could sustain up to 1.66x1011 bone marrow derived hMSCs. Knowing this, scaling
of the system is very possible, and the limiting factors would be surface area and
nutrients in media rather than oxygen transfer.
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Using Péclet number we can conclude that mass transfer varies slightly within the lattice
based on the channel orientation. In horizontal connecting channels mass transfer of air is
mainly accomplished through passive diffusion, while vertically oriented channels are
predicted to have more transfer through advection.

5.6 CONCLUSION
Here we have successfully modeled the 3D PLA lattice used to culture hMSCs. This
modeling allows us to better characterize and understand the forces at play in this system.
For future experiments CFD will be invaluable for scaling the system. In silico modeling
of larger matrix inserts and smaller fiber diameters will allow rapid testing without using
consumables.
The system shows marginally better KLa than comparable systems, including stirred
systems commonly used with microcarrier culture of stem cells. This increase may be due
in part to the unique way the cell culture scaffold is suspended outside of the media,
resulting in only a very thin layer of media between the cells and atmosphere.
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Figure 5-1: Scaffold Modeling used for CFD. A) Image of 3D printed PLA lattice. B) design of 2D model
and mesh comprised of nodes and quadrilaterals used to solve for fluid motion and forces.
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Figure 5-2: PLA Lattice used in bioreactor culture. A) Solidworks mock-up of lattice. B) 3D printed lattice
showing removable piece halfway retracted from the lattice body.
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Figure 5-3: Dye testing of flow through lattice matrix. Fluid velocity calculated to me 0.00368m s-1 was
tested using transient modeling on FLUENT in Ansys 18.2 as an inlet patch. This was compared to dye
tests at the same flow rate (Middle row). Bottom row is the same as top row, only dye is provided
continuously.
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Figure 5-4: Inlet Flow Rate vs Average Wall Shear. Modeled in ANSYS Fluent and graphed in Excel.
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Figure 5-5: CFD modeling of lattice matrix. A) Velocity contour and B) wall shear stress. Maximum
velocity of 0.0039m/s and maximum shear stress of 0.0056 dynes cm -2 measured inside the lattice,
excluding the inlet and outlet. Shear was calculated by multiplying strain rate by the viscosity of the fluid.
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Table 5-1: Flow rate vs average and maximum shear stress

Flow Rate
mL min-1

Average Shear Stress Maximum Shear
Stress
-2
Dynes cm
Dynes cm-2

0.125

0.00131

0.00252

0.25

0.00306

0.00589

0.5

0.00416

0.00799

0.75

0.00665

0.01274

1

0.00831

0.01591
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Figure 5-6: Kla calculation plot showing ln(C*-C) vs flow rate vs time. Resulting slope is the Kla hr-1.
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6 CONCLUSION
In this work we have designed and characterized a novel 3D culture system for the
proliferation of mesenchymal stem cells (hMSCs). The system consists of a cylindrical
body made of clear polycarbonate. It is capped by two plates on either side, with a
passthrough port to allow sampling of the scaffold. The system allowed for media
circulation through external peristaltic pumping.
The scaffold area chosen for studies was a 3D printed polylactic acid (PLA)
thermoplastic lattice printed on a hobbyist printer. The lattice was made as a
crosshatching grid, increasing surface area substantially. PLA was chosen for its special
properties, including: ease of printing, similar rigidity to cancellous bone,
biocompatibility and biodegradability. Cells readily adhered to the polymer and were
easily removed from it as well, a key consideration when the cell is the product of the
system.
The system worked better for hypoxic priming of the cells compared to a conventional
static hypoxia chamber. And overall this hypoxic preconditioning of the hMSCs resulted
in increased yields, averaging 4-fold over seeding density without detrimentally
impacting stemness. After seven days of culture the stem cells retained their cell surface
biomarker (CD105+ CD73+ CD19- CD14-) and could still give rise to adipocytes,
chondrocytes, and osteocytes after 21-day induction in specified medias. Of the oxygen
mixes used, we found a 1.5% O2 in nitrogen worked best when exposure was kept to a 3
days and the recirculation was kept at 0.25mL min-1. This resulted in the best and most
reproducible results.
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To understand the reactor better we employed CFD to elucidate flow and hydrodynamic
forces. This allowed us to simulate fluid movement through the small geometries of the
lattice. What we saw was that fluid was moving uniformly and slow through the lattice,
resulting in very low shear. The KLa of the system matched other reported values for
other passively aerated systems. Overall, a lattice of this design suspended out of the
media lead to an ideal low shear environment for stem cell culture while retaining high
cell purity and viability.
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7 FUTURE DIRECTION
Testing of other coatings should be performed on the PLA. With gelatin we were able to
form monolayers very easily, but it is till derived from animal sources. What I suggest is
to revisit the plasma treatment on PLA combined with a xeno-free coating. The plasma
treatment drastically increases the wettability of the scaffold, which would help combat
the drying of the lattice and allow better seeding. It would also eliminate animal sources
from the system if combined with serum free media. To do this I would treat the lattice in
the plasma cleaner as described before, but instead of PBS washing and plating the cells
directly onto the scaffold I would use the resulting charge to coat the PLA with another
polymer. The two that come to mind are poly-lysine and PNIPAAM. Poly-lysine has
been used to coat tissue culture plastics, which hMSCs will ready adhere to and grow on.
It is not derived from animals, a huge benefit if any hMSC based product is to go to the
FDA. PNIPAAM is a thermoresponsive polymer and would allow non-enzymatic lifting
of cells. This would eliminate the use of enzymes, which are either animal derived, or
recombinant and not very scalable due to price.
I also suggest scaling of the matrix. As a next step the lattice matrix diameter should be
increased and tested. CFD would be very helpful in finding the limit of diameter both for
fluid infiltration in the horizontal, and for oxygen diffusion. What I see happening is
having a larger diameter matrix with more sampling shelves, but also some larger 5.0mm
through channels running in the horizontal axis for gas exchange. To better understand
the fluid mechanics in such a system a more complete 3D model would have to be made.
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This would better elucidate lateral and horizontal movement of the media inside of the
lattice.
Lastly, I would have liked to harvest the secretome of the cells grown in this system.
Exosomes have shown much promise in wound healing and have great potential in
treating diseases. The regulator pathway for a product like this would be much clearer
than with a whole cell therapy. What I suggest is seeding and culturing the cells as
previously described, but omitting the cell lifting strategies. Instead, a tangential flow
filter or alternating flow filter should be placed in the line with pores ranging from 50 to
500nm. A secondary peristaltic pump could control permeate, meaning that the flow rate
of the reactor itself would not have to be adjusted. This would allow controlled passage
of cell exosomes, which could be collected very easily. As cells are immobilized on the
scaffold, there should theoretically be very little cell debris reaching the filter. As the
only byproduct of PLA degradation is lactic acid, as long as pH is monitored well there
should be low scaffold-based cytotoxicity resulting in undamaged exosomes.
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shell of a car to a 1970’s classic. Tinkering with the parts and learning the mechanics of the car
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guidance of Dr. M. Ian Phillips, his Ph.D. focused on the design, development, and operation of a
scalable, novel stem cell bioreactor for potential allogeneic cell therapies. Going forward,
Andrew is excited about developing novel technologies and processes for generating stem cells to
positively impact medical research in emerging therapeutics.
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9 SUPPLEMENTAL DATA

Figure 9-1: hMSC on 3D printed 3D filament. Cells cultured in bioreactor at 0.25mL min-1 for 7 days with a 3 day
1.5%O2 prime. Actin is in red and nuclei are in blue. Note actin filament alignment running diagonal following the
length of the PLA structure.
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Figure 9-2: hMSC on 3D printed 3D filament. Cells cultured in bioreactor at 0.25mL min -1 for 7 days with a 3 day
1.5%O2 prime. Actin is in red and nuclei are in blue. Note actin aligns with the bend of the PLA structure.
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Figure 9-3: hMSCs cultured on polystyrene tissue culture dishes for 7 days. Green is actin staining and blue are nuclei.
Note the random alignment of actin filaments.
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Figure 9-4: Total surface area vs diameter of 3D printed lattice insert. Calculated via Solidworks modeling.
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Figure 9-5: hMSC characterization of normoxic and hypoxic culture. Cells grown statically for 7 days on
polystyrene tissue culture dishes and characterized via flow cytometry. Hypoxic treatment was for three
days at 1.5% O2. Red is normoxia and blue is hypoxia. The third column is the overlay of the first two
columns for easier comparison.
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Figure 9-6: hMSC unstained Controls. Cultured for 7 days on polystyrene tissue culture dishes.
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Figure 9-7:Stained control hMSCs. Cells cultured for 7 days on tissue culture polystyrene dishes and stained with
hMSC markers according to protocol.
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Figure 9-8: Flow Cytometer of 21% O2 bioreactor cultured for 7 days at 0.25mL min-1.
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Figure 9-9: Flow Cytometry of hMSC primed at 0% O2 for three days and cultured for a total of seven days
in bioreactor at 0.25mL min-1.
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Figure 9-10: Flow Cytometry of hMSC primed at 1.5% O2 for three days and cultured for a total of seven
days in bioreactor at 0.25mL min-1.
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Figure 9-11: Flow Cytometry of hMSC primed at 5.0% O2 for three days and cultured for a total of seven
days in bioreactor at 0.25mL min-1.
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